A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Phase: PHASE2
Conditions: Astrocytoma
Sponsor: The University of Texas Health Science Center at San Antonio

 
 
 
 
 
 
COVER PAGE FOR PROTOCOL AND STATISTICAL ANALYSIS PLAN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Official Study Title: A Phase 2 Investigator Initiated Study to Determine the 
Efficacy and Safety of TVB‐ 2640 in Combination with Bevacizumab in Patients 
with First Relapse of High Grade Astrocytoma 
 
 
 
NCT number: NCT 03032484 
 
 
 
 
IRB Approval Date: 07/16/2018 
 
 
 
 
Unique Protocol: CTMS# 16‐0136 (20170090HU) 

 
 
 
 
TITLE: A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 
in Combination with Bevacizumab in Patients with First Relapse of High Grade Astrocytoma 
 
STUDY CENTER: Mays Cancer Center Institute for Drug Development 
7979 Wurzbach Rd. 
4th Floor Zeller Building 
San Antonio, TX 78229 
 
 
PRINCIPAL INVESTIGATOR: Andrew Brenner, MD, PhD 
Mays Cancer Center, 
Institute for Drug Development 
7979 Wurzbach Road, 4th Floor 
Mail Code# 8232 San Antonio, TX 78229 
Tel. (210) 450-5936 
Fax. (210) 692-7502 
E-mail: brennera@uthscsa.edu 
 
 
COINVESTIGATOR: 
Adolfo E. Diaz-Duque, MD 
Mays Cancer Center 
7979 Wurzbach Road, 4th floor 
Mail Code# 8232. San Antonio, TX 78229 
Tel: (210) 450-1667 
Email:  diazduque@uthscsa.edu 
 
 
STATISTITIAN: 
Joel Michalek, PhD 
Mays Cancer Center 
7979 Wurzbach Road 
San Antonio, TX 78229 
Tel: (210) 567-0886 
Email:  michalekj@uthscsa.edu 
 
 
 
IND#:  134370 
PROTOCOL: Version 6.0, July 12, 2018 

Page 2 of 60 
Protocol Version 6.0 
 
INVESTIGATOR’S AGREEMENT 
 
I have read and understand the contents of this clinical protocol for Protocol UTHSCSA CTMS# 16-0136 
and will adhere to the study requirements as presented, including all statements regarding confidentially. In 
addition, I will conduct the study in accordance with current international conference on harmonization 
(ICH) guidance, Good Clinical Practice (GCP) guidance, the Declaration of Helsinki, US Food and Drug 
Administration (FDA) regulations and local IRB and legal requirements. 
 
 
 
 
Name of Clinical Investigator: Andrew Brenner, MD, PhD 
 
Institution: Mays Cancer Center 
 
 
 
 
 
Investigator Signature 
Date 

Page 3 of 60 
Protocol Version 6.0 
 
 
ABBREVIATIONS 
 
AE 
Adverse Event 
BISR 
Biostatistics and Informatics Shared Resource 
DSM 
Data Safety Monitoring 
DSMB 
Data Safety Monitoring Board 
DSMC 
Data Safety Monitoring Committee 
DSMP 
Data Safety and Monitoring Plan 
DSO 
Data and Safety Officer 
DQA 
Director of Quality Assurance 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
IIS 
Investigator Initiated Protocol 
IND 
Investigational New Drug 
IRB 
Institutional Review Board 
NCI 
National Cancer Institute 
QAD 
Quality Assurance Division 
PALS 
Priority of Audit Level Score 
PI 
Principal Investigator 
PRC 
Protocol Review Committee 
PRMS 
Protocol Review and Monitoring System 
PSD 
Pharmacokinetic Sampling Department 
SAE 
Serious Adverse Event 
UPIRSO 
Unanticipated Problem Involving Risks to Subjects or Others 
UTHSCSA 
University of Texas Health Science Center at San Antonio 

Page 4 of 60 
Protocol Version 6.0 
 
Contents 
SYNOPSIS ....................................................................................................................................................... 6 
1. 
OBJECTIVES AND ENDPOINTS: ....................................................................................................... 13 
 
1.2 
Secondary Objective ........................................................................................................................... 13 
1.3 
Exploratory Objective ......................................................................................................................... 13 
1.4 
Primary Endpoint: ............................................................................................................................... 13 
1.5 
Secondary Endpoint: ........................................................................................................................... 13 
1.6 
Exploratory Endpoints: ....................................................................................................................... 13 
2. 
BACKGROUND: ................................................................................................................................... 13 
FATTY ACID METABOLISM IN HYPOXIA ............................................................................................. 15 
2.2 TVB-2640 ................................................................................................................................................. 16 
2.3 Rationale ................................................................................................................................................... 18 
2.4.1 Rationale for Dose Selection TVB-2640 ............................................................................................ 19 
2.4.2 Rationale for Dose selection Bevacizumab (Avastin)......................................................................... 19 
3. 
PATIENT SELECTION ......................................................................................................................... 19 
4. 
RANDOMIZATION .............................................................................................................................. 21 
5. 
STUDY DESIGN AND METHODS...................................................................................................... 21 
 
5.2 
Treatment Regimens ........................................................................................................................... 22 
5.2.2 Bevacizumab (Avastin)....................................................................................................................... 23 
5.2.3 Dose Modifications ............................................................................................................................. 23 
5.2.4 Concomitant Medications ................................................................................................................... 24 
5.2.5 Excluded Medications......................................................................................................................... 24 
5.2.6 Permitted Medications ........................................................................................................................ 25 
6. 
PROCEDURES ...................................................................................................................................... 25 
6.1 
Treatment Period Cycles 1 – 6 ............................................................................................................ 26 
6.2 
Study Termination / Early Study Termination and Survival Follow up. ............................................ 28 
6.3 
Assessment of Safety .......................................................................................................................... 29 
7 
PHARMACEUTICAL INFORMATION ............................................................................................... 31 
7.2 
Study Drug Packaging and Labeling .................................................................................................. 31 
7.3 
Study Drug Storage............................................................................................................................. 32 
 
7.4 
Study Drug Accountability ................................................................................................................. 32 
7.5 
Study Drug Dose and Administration ................................................................................................. 32 
8 
MANAGEMENT OF INTERCURRENT EVENTS .............................................................................. 33 
8.1 
Grading of Toxicity and Monitoring/Treatment of Toxicity .............................................................. 33 
8.2 
Adverse Events ................................................................................................................................... 33 
8.3 
Concomitant and Excluded Therapy ................................................................................................... 39 

Page 5 of 60 
Protocol Version 6.0 
 
9 
REMOVING SUBJECTS FROM THE STUDY.................................................................................... 39 
9.2 
Documentation.................................................................................................................................... 40 
9.3 
For Participants who withdraw early .................................................................................................. 40 
9.4 
Replacement of Subjects ..................................................................................................................... 40 
10 
CONDITIONS FOR INITIATING, MODIFYING, OR TERMINATING THE STUDY ................ 40 
10.2 
Informed Consent................................................................................................................................ 40 
10.3 
Modifications ...................................................................................................................................... 41 
10.4 
Deviations ........................................................................................................................................... 41 
10.5 
Termination......................................................................................................................................... 41 
11 
INVESTIGATOR'S RESPONSIBILITIES ........................................................................................ 41 
11.2 
Confidentiality .................................................................................................................................... 42 
11.3 
Institutional Review ............................................................................................................................ 42 
 
11.4 
Informed Consent and permission to use protected Health Information............................................. 43 
11.5 
Source Documentation and Investigator Files .................................................................................... 43 
11.6   Data Safety Monitoring Plan ................................................................................................................ 44 
12 
STATISTICAL CONSIDERATIONS ................................................................................................ 48 
13. REFERENCES ......................................................................................................................................... 49 
14. STUDY CALENDAR .............................................................................................................................. 53 

Page 6 of 60 
Protocol Version 6.0 
 
 
SYNOPSIS 
 
Title of Study: 
A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB-2640 in 
Combination with Bevacizumab in Patients with First Relapse of High Grade Astrocytoma. 
Investigators: 
PI: Andrew Brenner M.D., Ph.D.; Co-PI: Adolfo E. Diaz M.D.; Statistician: Joel Michalek Ph.D. 
Study Center(s): 
The trial will be conducted at the Mays Cancer Center in San Antonio, TX 
Concept and Rationale: 
The mainstay of treatment for GBM remains surgical removal followed by combined 
Chemotherapy with temozolomide and radiation therapy. Median and 2-year survival rates for 
patients receiving temozolomide were increased by 2.5 months (12.1 to 14.6 months) and 16.1% 
(10.4% to 26.5%), respectively. (4). However, once a patient progresses standard front-line 
therapy, prognosis is very poor and new therapies are needed. In the era of targeted therapies, 
clinical studies have demonstrated anti-tumor activity in patients treated with anti-angiogenic 
agents such as with bevacizumab, a recombinant human monoclonal antibody against VEGF 
receptor. Bevacizumab was FDA approved in 2009 as treatment for recurrent Glioblastoma 
following failure of radiation therapy and temozolomide, although the responses are not very 
long-lasting. (28). Median progression-free survival (PFS) on the first bevacizumab-containing 
regimen was 124 days (95% confidence interval (CI), 87–154 days); 6-month (6M)-PFS was 
33%. (2) 
In an effort to find alternate ways of treatment that might give the patients more durable 
responses, investigators have looked at the biologic behavior of GBM and have detected the 
presence of mobile lipids by proton magnetic resonance spectroscopy (1H MRS) in animal and 
human tumors, in cultured cells, in biopsies and in vivo (22). Moreover, it has been proposed 
that these lipid droplets could represent a temporary storage compartment (final storage 
compartment if the tissue does not recover) of fatty acids in the form of triglycerides. Under 
hypoxic or ischemic conditions, beta oxidation of fatty acids would cease.(1) 
The relevance of the above findings was such that the research community started to look at the 
relation between fatty acids and catalytic enzymes at cellular level. Fatty acid synthase (FASN) 
is a homodimeric and multi-functional enzyme that catalyzes the biosynthesis of palmitate in a 
NADPH- dependent reaction. Published studies have confirmed that many solid and 
hematopoietic tumors overexpress fatty acid synthase (FASN), including non-small cell lung, 
breast, ovarian, prostate, colon, pancreatic cancers, non-Hodgkin lymphoma as well as gliomas 
(34). 

Page 7 of 60 
Protocol Version 6.0 
 
 
TVB-2640 emerges as a novel agent that selectively inhibits FASN, enhancing tumor growth 
inhibition and viability of tumor cells by inducing tumor cell apoptosis via multiple mechanisms 
of action, both in vitro and in vivo, while having minimal effects on non-tumor cells. TVB-2640 
has been tested in murine models and lately in a phase 1, international, multi-center, open-label, 
dose-escalation study where the MTD was established and recommended for further 
investigation in Phase 2. (36) 
Since the progression free survival is not very long lasting on bevacizumab for patients with 
relapsed high-grade glioma; this phase 2 study will evaluate the potential effectiveness and 
safety of TVB-2640 in combination with bevacizumab. 
Primary Objective(s): 
To determine if the progression-free survival of patients with High Grade Astrocytoma who are 
treated with TVB-2640 in combination with bevacizumab is superior to treatment with 
bevacizumab alone. 
Secondary Objective(s): 
To evaluate the safety of TVB-2640 in combination with bevacizumab in patients with 
High Grade Astrocytoma. 
Exploratory Objective: 
To determine the extent by which TVB-2640 is able to penetrate the blood brain barrier 
where it might have the opportunity to affect tumor tissue metabolism. 
Primary Endpoint(s): 
Time from study enrollment to the first occurrence of relapse, progression, or death from any 
cause, or until last contact (if no event occurs). 
Secondary Endpoint(s): 
Adverse events and serious adverse events, graded according to NCI - Common Terminology 
Criteria for Adverse Events (CTCAE version 4.03). 
Exploratory Endpoint: 
Metabolic change analysis of tumor tissue by MR-Spectroscopy. 
Study Design: 
• 
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus 
Bevacizumab alone. 

Protocol Version 6.0 
 
Schema: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of Patients: 
 
• On average, will expect to accrue 1 to 2 patients a month for a total of 24. 
• It will take approximately 12 to 18 months to complete accrual. 
 
Main Criteria for Inclusion/Exclusion: 
INCLUSION CRITERIA 
• At least 18 years of age 
• Ability to understand the purposes and risks of the study and has signed a written 
informed consent form approved by the investigator’s IRB/Ethics Committee. 
• Histologically confirmed high-grade astrocytoma. 
• Progression following standard combined modality treatment with radiation and 
temozolomide chemotherapy. 
 
 
 
 
Page 8 of 60 

Protocol Version 6.0 
 
• Recovered from reversible toxicities of prior therapy to Grade 0 or Grade 1. 
• ECOG Performance Status of 0 to 2. 
• Life expectancy of at least 3 months. 
• Adequate renal and liver function: 
o AST/ALT ≤ 3 x ULN 
o Bilirubin ≤ 1.5 times ULN 
o Creatinine ≤ ULN 
• Adequate hematologic status (without hematologic support): 
o Hemoglobin ≥ 9 g/dL 
o ANC ≥ 1500 cells/ml 
o Platelets ≥ 100,000 cells/ml 
• All women of childbearing potential must have a negative serum pregnancy test and 
male and female subjects must agree to use effective means of contraception (for 
example, surgical sterilization or the use of barrier contraception with either a condom 
or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from 
entry into the study through three months after the last dose. 
 
EXCLUSION CRITERIA 
 
• Receiving warfarin (or other coumarin derivatives) and is unable to switch to low 
molecular weight heparin (LMWH) before the first dose of study drug. 
• Evidence of acute intracranial or intratumoral hemorrhage either by MRI or CT scan. 
Subjects with resolving hemorrhage changes punctuate hemorrhage, or hemosiderine are 
eligible. 
• Unable to undergo MRI scan (e.g., pacemaker). 
• Received enzyme-inducing anti-epileptic agents within 14 days of study drug (e.g., 
carbamazepine, phenytoin, phenobarbital, primidone). 
• Not recovered to a NCI CTCAE v.4.03 Grade ≤ 1 from AEs (except alopecia and 
lymphopenia) due to surgery, antineoplastic agents, investigational drugs, or other 
medications that were administered prior to study drug. 
• Evidence of wound dehiscence. 
• Pregnant or breast-feeding. 
• Clinically significant Dry Eye or necessary contact lens use 
• Serious intercurrent illness such as: 
o Hypertension (two or more blood pressure readings performed at screening 
of > 150 mmHg systolic or > 100 mmHg diastolic) despite optimal 
treatment. 
o Non-healing wound or ulcer 
o Uncontrolled life threatening cardiac arrhythmias. 
o Untreated hypothyroidism. 
o Uncontrolled active infection. 
o Symptomatic congestive heart failure or unstable angina pectoris within 3 
months prior to study drug. 
o Myocardial infarction, stroke, transient ischemic attack within 6 months. 
 
Page 9 of 60 

Page 10 of 60 
Protocol Version 6.0 
 
o Gastrointestinal perforation, abdominal fistula, intra-abdominal abscess 
within 1 year. 
 
• Inherited bleeding diathesis or coagulopathy with the risk of bleeding. 
• HIV, Hepatitis B or C documented infections. 
• Received any of the following prior anticancer therapy: 
o Non-standard   radiation   therapy   such   as   brachytherapy,   systemic 
radioisotope therapy (RIT), or intra-operative radiotherapy (IORT). Note: 
stereotactic radiosurgery (SRS) is allowed. 
o Non-antiangiogenic therapy (including investigational agents and small 
molecular kinase inhibitors) within 7 days or 5 half-lives, whichever is 
shorter, prior to the first dose of study drug. 
o Biologic agents (antibodies, immune modulators, vaccines, cytokines) 
within 21 days prior to first dose of study drug 
o Nitrosoureas or mitomycin C within 42 days or metronomic/protracted 
low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy 
within 28 days, prior to first dose of study drug. 
o Prior treatment with TVB-2640 
o Prior treatment with Carmustine Wafers 
 
Intervention and Mode of Delivery: 
 
Patients with documented High Grade Astrocytoma in first relapse, naïve to bevacizumab, will 
be randomized into 2 separate arms: 
 
• Patients randomized to Arm number one will receive Bevacizumab every 2 weeks in 
combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg cap dose), from 
day 1 until day 28 of the first cycle. 
• Patients randomized to Arm number two will receive Bevacizumab alone every 2 weeks, 
on days 1 and 15 of the first day 28 cycle. 
• MR-Spectroscopy will be obtained on patients (both arms) -7 to day -1 before and again 
from day 21 to day 28 of cycle 1. (Optional- at the Investigator’s discretion) 
• Starting on cycle 2 day 1, all patients will converge to a single arm and will continue to 
receive bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 
daily (rounded to 50mg cap dose) for up to 6 cycles.  Every cycle will last 28 days. 
• The  initial  Bevacizumab  dose  will  be  infused  over  90  minutes.  Infusion  may  be 
shortened to 60 minutes if the initial infusion is well tolerated. The third and subsequent 
infusions may be shortened to 30 minutes if the 60 minute infusion is tolerated well. 
Bevacizumab will be administered on days 1 and 15 of each cycle. 

Page 11 of 60 
Protocol Version 6.0 
 
Duration of Intervention and Evaluation: 
 
Subjects will be allowed to continue treatment on study for up to six cycles (28 days each) or 
until they have evidence of significant treatment-related toxicity or progressive disease. 
 
Subjects will receive study drug TVB-2640 and will be assessed for adverse events at all visits. 
Adverse events will be reported for all events occurring after the start of treatment until 30 days 
after study drug is discontinued or subsequent cancer therapy is initiated. Tumor assessments 
will be performed after every even cycle during treatment. 
 
Statistical Methods: 
 
This is a prospective, randomized, phase 2 study of TVB-2640 in combination with 
bevacizumab or bevacizumab alone in patients in first relapsed high grade astrocytoma. Analysis 
will be intent-to-treat of all randomized patients. 
 
Evaluability : All randomized patients will be included in the intent-to-treat analysis of the PFS 
 
 
POWER CALCULATIONS, ACCRUAL RATE, AND STUDY DURATION 
 
The median time to progression of patients treated with Bevacizumab is 124 days (95% 
confidence interval: 87–154 days) (19). A total sample size of 24 evaluable patients enrolled 
within 1 – 1.5 years) will provide 91.6% power to detect a 4 month difference in the median 
time to progression (3 months for bevacizumab alone (historic controls) versus 7 months in 
TVB-2640 in combination with bevacizumab, i.e., a hazard ratio of 0.43) using a one-sided log- 
rank test with alpha=0.1. 
 
We expect to accrue 1 to 2 patients a month, i.e. about 12 to 24 patients per year. The 24 patients 
can be enrolled in 1 – 1.5 years. With an additional 3 months of follow-up on the last patient, 
the total study duration is about 18 months. 
 
The primary efficacy analyses for estimation of PFS rates will be performed using a one sided 
log-rank test for an overall type-I error at 0.1 for each treatment group and a power of 91.6%. 
Thus far we will be able to reject the null hypothesis that the experimental and control survival 
curves are equal. 
 
a)  Definition of primary outcome/endpoint: 
Progression-free survival time of patients is defined as time from study enrollment to the first 
occurrence of relapse, death from any cause or until last contact (if no event occurs). 
 
 
b)  Definition of secondary outcomes/endpoints: 
Adverse events and serious adverse events, graded according to NCI - Common Terminology 
Criteria for Adverse Events version (4.03). 
 
c)  Exploratory Endpoint: Metabolic tumor changes on patients treated with TVB-2640. 

Page 12 of 60 
Protocol Version 6.0 
 
 
d)  Analytic plan for primary objective: 
We will test that the combination of bevacizumab and TVB-2640 versus bevacizumab alone 
will increase the rate of PFS, by using a non-parametric test (Log-Rank), with alpha of 0.1 and 
power of 91.6%. 
 
e)  Analytic plan for secondary objectives: 
Toxicities will be tabulated by type and grade according to NCI CTCAE v. 4.03 
 
f) Sample size justification: 
A sample size of total 24 evaluable patients will provide 91.6% power to detect a 4 month 
difference in the median time to progression (3 months for bevacizumab alone versus 7 months 
in TVB-2640 in combination with bevacizumab, i.e., a hazard ratio of 0.43) using a one-sided 
log-rank test with alpha=0.1. 
 
Funding, Regulatory, and Feasibility Issues: 
 
TVB-2640 is supplied by the manufacturer as 50 mg and 200 mg strength capsules. Additional 
formulations of TVB-2640 may be introduced, when available. The bevacizumab will be 
obtained by the Mays Cancer Center through commercial supply. 

Page 13 of 60 
Protocol Version 6.0 
 
1.   OBJECTIVES AND ENDPOINTS: 
 
1.1 Primary Objective 
 
To determine if the progression-free survival of patients with High Grade Astrocytoma who are 
treated with TVB-2640 in combination with bevacizumab is superior to treatment with 
bevacizumab alone. 
 
1.2 Secondary Objective 
 
To evaluate the safety of TVB-2640 in combination with bevacizumab in patients with High Grade 
Astrocytoma. 
 
1.3 Exploratory Objective 
 
To determine the extent by which TVB-2640 can metabolically affect tumor tissue. 
 
1.4 Primary Endpoint: 
 
Time from study enrollment to the first occurrence of relapse, progression, or death from any 
cause, or until last contact (if no event occurs). 
 
1.5 Secondary Endpoint: 
 
Adverse events and serious adverse events, graded according to NCI - Common Terminology 
Criteria for Adverse Events version (4.03). 
 
1.6 Exploratory Endpoints: 
 
Metabolic change analysis of tumor tissue by MR-Spectroscopy. 
Serum metabolomic changes. 
 
 
2.   BACKGROUND: 
 
2.1. High Grade Glioma 
 
Standard front-line treatment for newly diagnosed GBM consists of maximal surgical resection of 
primary tumor, followed by radiation therapy (RT; 2 Gy for 5 days a week, total 60 Gy) with 
concurrent temozolomide (TMZ, alkylating agent) at 75 mg/m2 PO daily for 6 weeks, followed by 
maintenance phase of single-agent temozolomide (150-200 mg/m2 PO daily on D1-5 for 6 cycles; 
28-day cycle).(3, 4) Temozolomide (a prodrug) is rapidly and non-enzymatically converted to the 
active alkylating metabolite MTIC ((methyl-triazene-1-yl) – imidazole-4-carboxamide). The 
cytotoxic effects of MTIC are manifested through alkylation of DNA at the O6, N7 guanine 
positions.  This multimodal treatment approach has remained the standard of care and is based on 

Page 14 of 60 
Protocol Version 6.0 
 
the EORTC phase III trial published by Stupp et al. more than a decade ago.(4) This landmark 
study demonstrated a median overall survival of 14.6 months in the TMZ group versus 12.1 months 
in the radiation alone treatment cohort. However, this still leaves much to be desired with an 
improvement in median survival of only 2.6 months over radiotherapy alone. At that time, 
radiation (RT) alone was considered standard of care in most countries. In the US, common 
practice was to add adjuvant nitrosurea-based chemotherapy regimen with a small survival benefit 
at the cost of significant adverse effects (AEs). In summary, GBMs are highly aggressive, vascular 
tumors associated with frequent relapses due to resistance to multimodality treatment. For 
recurrent and relapsing GBM, there is no clear standard of care to date. 
 
It is also well accepted that brain tumors rely on vascularization for survival and continued growth. 
While normal brain vasculature is a highly organized structure of endothelial cells, pericytes, and 
astrocytes forming a tight barrier which restricts access to the intracerebral system, GBM displays 
markedly disorganized vascular structures with conspicuous endothelial cell proliferation, pericyte 
and basement membrane abnormalities resulting in permeability with heterogenous leakiness and 
abnormal blood flow.(5) This aberrant process of endothelial proliferation and loss of the blood 
brain barrier is related to the expression of vascular endothelial growth factor (VEGF) by the tumor 
cells as well as the cells in the surrounding microenvironment in response to hypoxia and acidosis. 
This leakiness results in an increased interstitial pressure and an impediment to drug delivery. By 
blocking VEGF signaling either through monoclonal antibodies to VEGF-A or inhibition of the 
VEGF receptors, it has been shown that prompt reduction in interstitial pressures can be achieved 
with presumed better drug delivery to tumor cells. While the role of VEGF signaling in 
angiogenesis has been extensively described, another role for VEGF has been proposed with 
carcinoma progression selecting for cells that depend on VEGF as a survival and migration 
factor.(6) This would explain the high frequency of VEGF receptor expression in GBMs and other 
solid tumors.(7) Targeting VEGF has proven to be clinically relevant in GBM. The addition of 
bevacizumab to standard RT-TMZ as first-line treatment for GBM was investigated in the 
AVAglio study.(8) In this study, the addition of bevacizumab to RT-TMZ improved progression 
free survival (PFS; 10.6 vs. 6.2 months, HR 0.64) compared with RT-TMZ alone, but resulted in 
increased toxicity without an improvement in overall survival (OS).(8) Similarly, the RTOG-0825 
Phase III study also showed a trend towards improved PFS with the addition of bevacizumab to 
RT-TMZ, but no OS benefit.(9) 
 
Despite advances in multimodal therapies, the median survival of patients with GBM is 
approximately 15 months with a 5 year survival rate of 5.0% after diagnosis.(10) Other current 
cytotoxic chemotherapeutic agents for GBM include: carmustine, lomustine or carboplatin.(11) 
Therapeutic agents targeting EGFR, VEGFR, PDGFR, Ras pathway, mTOR, histone acetylation 
and integrins (12) are under current investigation; but these therapies have resulted in poor to 
modest clinical response at best.(13) Identification of more potent and effective therapeutic agents, 
either as a single agent or in combination with existing drugs, is clearly needed for the clinical 
advancement of GBM. 
 
Hypoxia promotes antiangiogenic resistance in glioblastoma. While normal brain vasculature is a 
highly organized structure of endothelial cells, pericytes, and astrocytes forming a tight barrier 
which restricts access to the intracerebral system, GBMs display markedly disorganized vascular 

Page 15 of 60 
Protocol Version 6.0 
 
structures with conspicuous endothelial cell proliferation, pericyte and basement membrane 
abnormalities resulting in permeability with heterogenous leakiness and abnormal blood flow(5). 
This aberrant process of endothelial proliferation and loss of the blood brain barrier is related to 
the expression of VEGF by the infiltrating margin of the tumor (14) as well as the cells in the 
surrounding microenvironment in response to hypoxia and acidosis. While targeting of VEGF has 
proven to be clinically relevant as discussed above, given the key importance of VEGF and its 
receptor VEGFR2 in angiogenesis, hopes were once raised that blocking this pathway would 
eradicate the tumor vasculature and heal cancer. This clearly has not been the case as clinical 
practice reveals that therapy with angiogenesis inhibitors, including bevacizumab which is the only 
FDA approved drug for recurrent glioblastoma, generally does not prolong survival of cancer 
patients for more than months. Increasing evidence points to the root cause of angiogenesis, 
hypoxia, as a driving force for resistance to anti-angiogenics. In a prospective clinical trial (15) of 
bevacizumab and irinotecan in which biomarkers were assessed, the most significant predictor 
(negative) of both response to therapy and overall survival was the presence of hypoxia induced 
carbonic anhydrase (CA9) (P(c2) = 0.020, HR 2.72, CI 1.17 to 6.36). Second to this was hypoxia- 
inducible factor 1-alpha (16). In a prospective clinical study in which the pan-VEGF receptor 
inhibitor AZD2171 was given to GBM patients (17), the most predictive blood biomarker of tumor 
progression was stromal derived factor 1a (18), suggesting that the correlation seen between 
progression on AZD2171 and presence of SDF1 is associated with increased hypoxia in human 
brain tumor spectra, with an associated increase in HIF1α, matrix metalloproteinases, chemokines 
and a more invasive phenotype(19-21). 
 
In order to better characterize the metabolic changes associated with resistance to bevacizumab 
and other antiangiogenics, we performed metabolomic profiling of tumors and sera from patients 
having failed glioblastoma. Interestingly, the most significant change that correlated with degree 
of hypoxia was an increase in the presence of long chain fatty acids (Figure A). This is not an 
entirely surprising finding as glioblastoma has been known to be a tumor type in which large 
inclusions of fatty acids (referred often to as lipid droplets) develop.(22) It has been proposed that 
these lipid droplets could represent a temporary storage compartment of fatty acids in the form of 
triglycerides that could serve as reservoir that could be relied upon under metabolic stress (1). 
 
FATTY ACID METABOLISM IN HYPOXIA 
 
The changes observed in fatty acids with hypoxia and bevacizumab resistance suggest a potentially 
targetable mechanism. The precursor for fatty acid synthesis is Acetyl-CoA. While Acetyl-CoA 
under normoxia is derived from glucose, hypoxia induces a shift toward the production from 
alternate precursors. When using 13C-glutamine in labelling of cells under hypoxia, citrate and 
fatty acids are found to be labelled (Fan et al, 2013). Citrate itself is the precursor for AcCoA, and 
can be used for fatty acid synthesis, suggesting glutamine as an alternate source during hypoxia. 
Interestingly, what is typically considered a waste product under hypoxia, acetate, has recently 
been identified as a carbon source which is scavenged in cancer. Specifically, it was found that the 
enzyme generating AcCoA from acetate, Acetyl-CoA synthetase 2 (ACSS2), is frequently 
amplified in a subset of cancers and is upregulated in cells exposed to hypoxic and low serum 
conditions (Schug et al, 2015). Consequently, labelling of lipogenic AcCoA and hence fatty acids 
from 13C-acetate was found to be increased in these conditions (Kamphorst et al, 2014; Schug et 
al, 2015). These findings have prompted the investigation into fatty acids and their synthetic 

Page 16 of 60 
Protocol Version 6.0 
 
enzymes. Fatty acid synthase (FASN) is a homodimeric and multi-functional enzyme that 
catalyzes the biosynthesis of palmitate in a NADPH- dependent reaction. (29) Normal cells in 
adult tissue ubiquitously express low to moderate levels of FASN; however, these cells, which 
primarily import lipids from the extracellular milieu, do not have a strict requirement for FASN 
activity. (30) In contrast, tumor cells have an increased requirement for lipids for functions such 
as membrane biosynthesis, protein modification, and signaling molecules. Consequently, tumor 
cells are more dependent on de novo palmitate synthesis catalyzed by FASN than normal cells. 
(31) 
 
Two classes of FASN exist: FASN I in eukaryotes and fungi, and FASN II in plants and 
prokaryotes. Animal FASN I is a homodimeric protein found in the cytosol of lipogenic tissues 
such as the liver and brain.(32) Oncologically speaking, published studies have confirmed that many 
solid and hematopoietic tumors overexpress fatty acid synthase (FASN), including non-small cell 
lung, breast, ovarian, prostate, colon, pancreatic cancers, non-Hodgkin lymphoma as well as 
Gliomas.(33) (34)  Moreover, FASN tumor expression has been found to be increased in a stage- 
dependent manner that is associated with diminished patient survival. (31) 
 
FASN selectively inhibits growth and viability of tumor cells by inducing tumor cell apoptosis via 
multiple mechanisms of action, both in vitro and in vivo, while having minimal effects on non- 
tumor cells such as fibroblasts, astrocytes, and endothelial cells, demonstrating that tumor cells 
have a unique dependence on FASN function for survival that is not present in normal cells. (33) 
(35) 
 
2.2 TVB-2640 
 
 
TVB-2640 is a potent and reversible inhibitor of the FASN enzyme that has been validated in 
multiple tumor cell lines, as well as in clinical studies. TVB-2640 inhibits the ketoacylreductase 
(KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH 
and Acetoacetyl-CoA in inhibiting KR activity. The pharmacokinetics (PK) and metabolism of 
TVB-2640 have been examined with a series of in vitro and in vivo studies, including toxicokinetic 
studies. 
Due to its rapid metabolism in the mouse, TVB-2640 cannot be tested in murine xenograft models. 
Thus, TVB-3166, a structural analog of TVB-2640 with similar pharmacological properties, was 
used as a surrogate molecule (parallel reagent) in murine xenograft models. In the PANC-1 murine 
xenograft tumor model, TVB-3166 administered orally once daily exhibited dose-dependent tumor 
growth inhibition, with significant tumor growth inhibition compared to vehicle-treated mice of 
57% seen at a dose of 100 mg/kg. At a dose of 30 mg/kg, tumor growth inhibition was lower (19%) 
and non-significant relative to vehicle control. (35) 
 
The pharmacokinetics (PK) and metabolism of TVB-2640 have been examined with a series of in 
vitro and in vivo studies, including toxicokinetic studies. Overall, the PK properties determined to- 
date for TVB-2640 demonstrate that it is orally absorbed in humans and has a mean half-life of 
approximately 15 hours. No potential for significant drug interaction has been identified. (26) 
 
In safety pharmacology studies, TVB-2640 had no effects on respiratory or central nervous system 
(CNS) function. TVB-2640 exhibited concentration-related inhibition of human ether-àgo-go- 

Page 17 of 60 
Protocol Version 6.0 
 
related gene (hERG) potassium channel currents and was characterized as a moderately potent 
hERG inhibitor. In conscious dogs, an oral dose of 1000 mg/kg caused slight, reversible 
prolongation of the QT/corrected QT (QTc) interval from 3 to 22 hours post dose; there were no 
effects noted at lower doses of 50 or 100 mg/kg. Single oral doses of TVB-2640 up to 1000 mg/kg 
were well tolerated in rats and dogs. Daily oral administration of TVB-2640 for 28 days was well 
tolerated in male rats at doses up to 250/300 mg/kg/day and in female rats at 30 mg/kg/day. TVB- 
2640 administration resulted in the deaths of two 250 mg/kg/day females on Study Days 15 and 
28. Test article-related clinical signs were noted primarily in ≥100 mg/kg/day females (skin and 
coat). Test article-related body weight loss and/or decreases in mean body weight gain and 
decreases in food consumption were noted in ≥100 mg/kg/day females. Treatment-related 
microscopic findings were identified in the lungs and stomach of females given ≥30 mg/kg/day 
and in the skin at ≥100 mg/kg/day. Lung and skin changes were still evident in high dose females 
after a 14-day recovery. The noobserved-adverse-effect level (NOAEL) was 250/300 mg/kg/day 
for males and 30 mg/kg/day for females. The severely toxic dose (STD) was 100 mg/kg/day for 
females, but the STD in males is >300 mg/kg/day. Plasma area under the curve (AUC) exposures 
were consistently higher in females compared to males with female/male ratios ranging from 2.25- 
to 3.47-fold. 
 
TVB-2640 has completed phase 1 testing both as a monotherapy and in combination with 
paclitaxel. A full description of clinical toxicity is available in the investigator brochure. As 
detailed in the table below, the most common (i.e., Incidence ≥10%) adverse events of any grade 
considered possibly, probably or definitely related to TVB-2640 among patients treated with TVB- 
2640 monotherapy include skin and subcutaneous tissue disorders, (78%); gastrointestinal 
disorders (65%), general disorders and administration site conditions (57%); eye disorders (50%); 
respiratory, thoracic, and mediastinal disorders (42%); metabolism and nutrition system disorders 
and nervous system disorders (each 36%); infections and infestations (31%); investigations (28%); 
and musculoskeletal and connective tissue disorders (22%). Few were grade 3, and included 
palmar-plantar erythrodysaesthesia syndrome, fatigue, anemia, and dyspnea. 

Page 18 of 60 
Protocol Version 6.0 
 
 
 
 
Based upon the non-overlapping toxicity profile with bevacizumab, it is expected that the toxicity 
profile of the combination should be similar to those of the individual agents. 
 
 
2.3 Rationale 
 
The mainstay of treatment for GBM remains surgical removal followed by combined 
chemotherapy with temozolomide and radiation therapy. Median and 2-year survival rates for 
patients receiving temozolomide were increased by 2.5 months (12.1 to 14.6 months) and 16.1% 
(10.4% to 26.5%), respectively.(4) However, once a patient fails standard front-line therapy, 
prognosis is very poor and new therapies are needed. In the era of targeted therapies, clinical 
studies have demonstrated anti-tumor activity in patients treated with anti-angiogenic agents such 

Page 19 of 60 
Protocol Version 6.0 
 
as with bevacizumab, a recombinant human monoclonal antibody against VEGF receptor. 
Bevacizumab was FDA approved in 2009 as treatment for recurrent Glioblastoma following 
failure of radiation therapy and temozolomide, although the responses are not very long-lasting. 
and no proven survival benefit has been seen in as many as 4 randomized clinical trials.(28) 
 
TVB-2640 emerges in the horizon as a novel agent that selectively inhibits FASN enhancing tumor 
growth inhibition and viability of tumor cells by inducing tumor cell apoptosis via multiple 
mechanisms of action, both in vitro and in vivo, while having minimal effects on non-tumor cells. 
TVB-2640 has been tested in murine models and lately in a phase 1, international, multi-center, 
open-label, dose-escalation study where MTD was established and recommended for further 
investigation in Phase 2.(36) 
 
Given the findings of: a) increased hypoxia with bevacizumab, b) increase in long chain fatty acids 
in the tumors of patients who have failed bevacizumab, and c) evidence suggesting that fatty acid 
metabolism could play a role in survival under hypoxia, it is rational that the addition of TVB- 
2640 could overcome acquired resistance to bevacizumab. Since the progression free survival is 
not very long lasting on bevacizumab for patients with relapsed high-grade glioma; this phase 2 
study will evaluate the potential effectiveness and safety of TVB-2640 in combination with 
bevacizumab compared to bevacizumab alone. 
 
2.4.1 Rationale for Dose Selection TVB-2640 
 
Based on results from previous studies, the MTD of TVB-2640 administered PO daily (q.d.) has 
been stablished as monotherapy and in combination on a 21 or 28 days cycle length respectively 
as 100 mg/m2 (based on BSA dosing). Particularly, protocol 3V2640-CLIN-002 was a phase 1, 
international, multi-center, open-label, dose-escalation study designed to evaluate the DLT and 
MTD of TVB-2640 administered PO and establish the TVB-2640 dose recommended for further 
investigation in phase 2 (i.e., RP2D) when given as monotherapy and in combination with selected 
commercially-available anticancer agents. In that protocol, patients with any histologically or 
cytologically confirmed solid tumor type were eligible and secondary objectives included 
characterization of the safety and PK profile of TVB-2640 and identification of preliminary anti- 
tumor activity in this patient population. Further data regarding dose selection of TVB-2640 can 
be found in the current Investigator Brochure (IB). Given the lack of significant overlap in toxicity 
profile with that of bevacizumab, the MTD has been selected as the phase 2 combination dose. 
 
2.4.2 Rationale for Dose selection Bevacizumab (Avastin) 
 
Phase II clinical studies as well as the FDA have established the standard bevacizumab dose of 10 
mg/kg IV every 2 weeks when treating patients with recurrent glioblastoma. 
 
3.   PATIENT SELECTION 
 
Inclusion Criteria 
• At least 18 years of age 
• Ability to understand the purposes and risks of the study and has signed a written 
informed consent form approved by the investigator’s IRB/Ethics Committee. 

Page 20 of 60 
Protocol Version 6.0 
 
• Histologically confirmed high grade astrocytoma. 
• Progression following standard combined modality treatment with radiation and 
temozolomide chemotherapy 
• Recovered from reversible toxicities of prior therapy to Grade 0 or Grade 1. 
• ECOG performance Status of 0 to 2. 
• Life expectancy of at least 3 months. 
• Adequate renal and liver function: 
o AST/ALT ≤ 3 x ULN 
o Bilirubin ≤ 1.5 x ULN 
o Creatinine ≤ ULN 
• Adequate hematologic status (without hematologic support): 
o Hemoglobin ≥ 9 g/dL 
o ANC ≥ 1500 cells/ml 
o Platelets ≥ 100,000 cells/ml 
• All women of childbearing potential must have a negative serum pregnancy test and male 
and female subjects must agree to use effective means of contraception (for example, 
surgical sterilization or the use of barrier contraception with either a condom or diaphragm 
in conjunction with spermicidal gel or an IUD) with their partner from entry into the study 
through three months after the last dose. 
 
 
Exclusion Criteria 
• Receiving  warfarin  (or  other  coumarin  derivatives)  and  is  unable  to  switch  to  low 
molecular weight heparin (LMWH) before the first dose of study drug. 
• Evidence of acute intracranial or intratumoral hemorrhage either by MRI or CT scan. 
Subjects with resolving hemorrhage changes, punctuate hemorrhage, or hemosiderine are 
eligible. 
• Unable to undergo MRI scan (e.g., pacemaker). 
• Received  enzyme-inducing  anti-epileptic  agents  within  14  days  of  study  drug  (e.g., 
carbamazepine, phenytoin, phenobarbital, primidone). 
• Not  recovered  to  a NCI CTCAE  v.4.03  Grade  ≤  1  from  AEs  (except  alopecia and 
lymphopenia) due to surgery, antineoplastic agents, investigational drugs, or other 
medications that were administered prior to study drug. 
• Evidence of wound dehiscence. 
• Pregnant or breast-feeding. 
• Clinically significant dry eye or contact lens use. 
• Serious intercurrent illness such as: 
o Hypertension (two or more blood pressure readings performed at screening of 
> 150 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment. 
o Non-healing wound or ulcer 
o Uncontrolled life threatening cardiac arrhythmias. 
o Untreated hypothyroidism. 
o Uncontrolled active infection. 
o Symptomatic congestive heart failure or unstable angina pectoris within 3 

Page 21 of 60 
Protocol Version 6.0 
 
months prior to study drug. 
o Myocardial infarction, stroke, transient ischemic attack within 6 months. 
o Gastrointestinal perforation, abdominal fistula, intra-abdominal abscess within 
1 year. 
• Inherited bleeding diathesis or coagulopathy with the risk of bleeding. 
• HIV, Hepatis B or C documented infections. 
• Received any of the following prior anticancer therapy: 
o Non-standard radiation therapy such as brachytherapy, systemic radioisotope 
therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic 
radiosurgery (SRS) is allowed. 
o Non-antiangiogenic  therapy  (including  investigational  agents  and  small 
molecular kinase inhibitors) within 7 days or 5 half-lives, whichever is shorter, 
prior to the first dose of study drug. 
o Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 
21 days prior to first dose of study drug 
o Nitrosoureas or mitomycin C within 42 days or metronomic/protracted low- 
dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 
days, prior to first dose of study drug. 
o Prior treatment with TVB-2640 
o Prior treatment with Carmustine Wafers 
 
 
 
4.   RANDOMIZATION 
 
This study will be performed at a single institution (UT Heath Cancer Center), where a permuted 
block randomization method will be used in order to allow flexibility in achieving balanced 
allocation of subjects among treatment groups. We will use small blocks of 4 patients and simple 
randomization will be done within each block. 
 
5.   STUDY DESIGN AND METHODS. 
 
5.1 Design 
 
Patients with documented High Grade Astrocytoma in first relapse, naïve to bevacizumab, will be 
randomized into 2 separate arms: 
 
• Patients randomized to Arm number one will receive Bevacizumab every 2 weeks in 
combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg cap dose), from 
day 1 until day 28 of the first cycle. 
• Patients randomized to Arm number two will receive Bevacizumab alone every 2 weeks, 
on days 1 and 15 of the first 28 day cycle. 
• MR-Spectroscopy will be obtained on patients (both arms) at day 28 +/- 3 days of first 
cycle. (Optional- at the investigators discretion) 
• Starting on cycle 2 day 1, all patients will converge to a single arm and will continue to 
receive bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 

Page 22 of 60 
Protocol Version 6.0 
 
daily (rounded to 50mg cap dose) for up to 6 cycles.  Every cycle will last 28 days. 
• The initial Bevacizumab dose will be infused over 90 minutes. Infusion may be shortened 
to 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions 
may be shortened to 30 minutes if the 60 minute infusion is tolerated well. Bevacizumab 
will be administered on Day 1 and Day 15 of each cycle. 
 
 
TVB-2640 will be administered on a once daily (QD) schedule. Each QD TVB-2640 dose is to be 
taken at the same time each day under fasted conditions (i.e., at least 2 hours after last food 
consumption and at least 1 hour before next food consumption), with each dose separated by 24 
hours (+/- 4 hrs).For TVB-2640 doses missed by more than 8 hours will not be made up, and 
patients will skip sand resume their schedule the following day. Dose delays for bevacizumab will 
be as per standard of care and at the direction of the treating physician. 
 
On scheduled study visit days, TVB-2640 is to be taken at the study center under the observation 
of study center personnel. On all other study days, patients are to self-administer TVB-2640. 
On study visit days when both TVB-2640 and bevacizumab are to be administered, TVB-2640 
should be taken approximately 2 hours prior to the initiation of the bevacizumab infusion. 
 
It is anticipated that patients will receive at least 1 cycle of TVB-2640. After cycle 1 patients may 
continue to receive TVB-2640 for up to 6 cycles or until development of progressive disease (PD), 
unacceptable toxicity or another withdrawal criterion is met. Patients who discontinue study drug 
are to attend a Final Study Visit 28 days (±5 days) after the last study drug dose. 
 
During the study, safety is to be evaluated by documentation of adverse events (AEs) and serious 
adverse events (SAEs), clinical laboratory tests (hematology, clinical chemistry, and urinalysis), 
physical examinations, vital signs measurements, Eastern Cooperative Oncology Group (ECOG) 
performance status, and 12-lead electrocardiograms (ECGs). 
 
5.2 Treatment Regimens 
 
5.2.1 TVB-2640 
 
TVB-2640 at a dose of 100 mg/m2 (rounded to 50mg cap dose) will be taken by mouth on day 1 
– 28 of each 28 day cycle. 
 
TVB-2640 is supplied by the manufacturer as 50 mg and 200 mg strength capsules. Additional 
formulations and of TVB-2640 may be introduced, when available. 
 
TVB-2640 initially will be administered on a QD schedule; thus, patients receiving TVB-2640 QD 
will receive 28 doses of TVB-2640 in each cycle. Each QD TVB-2640 dose is to be taken at the 
same time of the day under fasted conditions (i.e., at least 2 hours after last food consumption and 
at least 1 hour before next food consumption), with each dose separated by 24 hours (±4 hours). 
On study visit days when both TVB-2640 and the combination anticancer agent are to be 
administered, TVB-2640 should be taken approximately 2 hours prior to the initiation of the 
anticancer agent administration 

Page 23 of 60 
Protocol Version 6.0 
 
5.2.2 Bevacizumab (Avastin) 
 
Bevacizumab will be administered intravenously at 10 mg/kg on day 1 and day 15 of every cycle, 
with the dose regimen documented in the CRF. Any required pre- or concurrent medication is also 
to be administered in accordance with the prescribing information and routine clinical practice. 
 
Prophylaxis against nausea and vomiting should be applied using a regimen intended for 
moderately emetogenic chemotherapy. 
 
5.2.3 Dose Modifications 
 
BEVACIZUMAB 
 
Please follow the package insert for all bevacizumab dose modifications and discontinuations. See 
Appendix C. 
 
TVB-2640 
 
 
• If a patient develops any toxicity grade 3 (including hematologic), then TVB-2640 will be 
placed on hold for up to 14 days. 
• If after 14 days, the patient has not improved from the above mentioned toxicity, then TVB- 
2640 will be kept permanently on hold until recovery of toxicity. 
• If the toxicity returns to < Grade 2 or baseline, and the decision is made that the patient can 
resume study drug, then TVB-2640 dosing should be restarted at a lower dose level. Dose 
reductions will be made in 25% increments. 
• If a subject requires more than 2 dose level reductions for non-hematological toxicity, 
he/she should discontinue from the study. Ongoing dose reductions beyond 2 dose levels 
are allowed for hematologic toxicity. 
• Any subject who misses more than one complete cycle (four weeks) for treatment-related 
toxicity should discontinue from the study. 
 
At each study center visit, the patient will be evaluated for possible toxicities that may have 
occurred since the previous visit. Toxicities are to be graded according to the NCI CTCAE, 
Version 4.03. If a toxicity is not classified in the CTCAE, then it should be classified according to 
the criteria presented in Section 8.2.2.1 Furthermore, the Investigator is to assess the relationship 
of a toxicity to study drug as described in the same section. 
 
 
 
The table below summarizes dose modifications for non-hematologic toxicities. 

Page 24 of 60 
Protocol Version 6.0 
 
 
 
 
 
5.2.4 Concomitant Medications 
 
All prescription and non-prescription medications and therapies, including pharmacologic doses 
of vitamins, herbal medicines, or other non-traditional medicines, taken from 28 days prior to the 
first dose of TVB-2640 through the Final Study Visit must be recorded in the CRF. 
 
5.2.5 Excluded Medications 
 
The following medications and treatments are prohibited during study participation. 
 
• Any investigational agent or device other than  TVB-2640, including agents that are 
commercially available for indications other than the. 
• In Monotherapy Cohort, any anti-neoplastic treatment with activity against solid tumors 
other than study drug. This includes high doses of corticosteroids for any reason other than 
brain metastases. 
• Strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4). (Refer to the following 

Page 25 of 60 
Protocol Version 6.0 
 
for examples: 
Drug Interactions & Labeling > Drug Development and Drug Interactions: Table of  
Substrates, Inhibitors and Inducers.) 
• Medications known or suspected to prolong the QT/QTc interval, with the exception of 
drugs with low risk of QT/QTc prolongation that are used as standard premedication (e.g., 
diphenhydramine, famotidine, ondansetron). (Refer to the following for examples: 
http://crediblemeds.org/everyone/composite-list-all-qtdrugs/?rf=US.) 
 
5.2.6 Permitted Medications 
 
Medications and treatments other than those specified in Section 5.2.5, including palliative and 
supportive care for disease-related symptoms, are permitted during the study. Patients should be 
closely monitored, and treatment is to be instituted for disease-related symptoms, as appropriate. 
 
 
6.   PROCEDURES 
 
A  summary of visits  and  clinical  procedures  is  found  in  Section 14. 
 
Subjects who withdraw from the study before all follow-up procedures have been performed 
will be managed and documented as described in Section 9, Removing Subjects from the Study. 
 
When a subject has completed the study termination or early termination visit, he/she and/or a 
family member will be contacted for survival information every 3 months until one year from first 
dose. 
 
All subjects will be screened within 21 days prior to Cycle 1 Day 1. Vital signs, clinical laboratory 
test results, weight and AEs will be used to assess safety. Efficacy will be assessed based on tumor 
assessments (objective response rate, progression-free survival  and duration of response) 
conducted at intervals during the study. Subjects who have not progressed after 6 cycles may be 
permitted to continue therapy on a case-by-case basis. 
During screening, candidates for the study will be fully informed about the nature of the study and 
possible risks, and will receive a copy of the informed consent for review. Candidates must read 
the consent form and sign the document after the investigator has answered all questions to the 
candidate's satisfaction. Further procedures can begin only after the consent form has been signed. 
The original signed consent form will be retained by the investigator and a copy will be given to 
the candidate. Candidates will be evaluated for entry into the study according to the stated inclusion 
and exclusion criteria (Section 3, Patient Selection). The investigator will evaluate the results of 
all examinations, including clinical laboratory tests, and will determine each candidate's suitability 
for the study. The investigator must know the baseline results before enrollment. The pregnancy 
test for females of reproductive potential must be negative for those subjects to proceed to 
enrollment. All screening procedures must be done within 21 days of cycle        1 day 1, unless 
otherwise specified. 
 
 
The following procedures will be performed to establish each candidate's general health and 
qualifications for possible enrollment into the study: 

Page 26 of 60 
Protocol Version 6.0 
 
 
* Obtain signed, written informed consent and permission to use protected health information, 
(in accordance with the Health Insurance Portability and Accountability Act or HIPAA). Refusal 
to sign informed consent and permission excludes an individual from the study. 
 
* Record medical history including cancer history: histology of tumor, date of GBM diagnosis, 
types and dates of prior anti-tumor therapy (including   surgery,   radiation   therapy,   systemic 
therapy), and date of most recent disease progression. 
 
* Record recent (taken within 28 days prior to C1D1) medication history, including vitamins, 
herbal preparations, blood products, and other over the counter (OTC) drugs. 
 
* Record  blood  pressure  (BP),  heart  rate  (HR),  respiratory rate  (RR)  and  temperature 
measurements. In subjects with known significant pulmonary disease, measure oxygen saturation 
using pulse oximeter after a 2 minute walk. 
 
* Perform a complete physical examination, including height and weight. 
 
* Assess Eastern Cooperative Oncology Group (ECOG) Performance Status score (see Appendix 
A, Eastern Cooperative Oncology Group Performance Status Scale) 
 
* Obtain a baseline CXR or Chest CT scan. 
 
 
* Obtain a baseline ECG to assess for cardiac arrhythmias or evidence of recent cardiac events. 
 
 
* Obtain a baseline Ophtalmologic Evaluation. 
 
* Draw blood samples for hematology, chemistry and coagulation. 
 
* Obtain a blood sample for serum HCG pregnancy test in female subjects of child- bearing 
potential (all female subjects unless surgically sterilized or at least 1 year post-menopausal). 
 
* Obtain a urine sample for urinalysis with microscopic analysis. 
 
* Perform tumor assessment with MRI of the brain per RANO criteria. (refer to Appendix B) 
 
* Review inclusion and exclusion criteria (see Section 3, Patient Selection). 
 
6.1 Treatment Period Cycles 1 – 6 
 
Study drug should be administered within ±2 days of the nominal time point. Lab tests used for 
determining dosing must be done within 5 days before the first dose of study drug (Cycle l/Day 
1), and within 3 days before Days 1 and 15 of all subsequent cycles. All other required study 
assessments should be obtained within 5 days of the nominal time point unless otherwise specified. 
Subjects must receive the first dose of study drug within 21 days of signing the informed consent 
form. 

Page 27 of 60 
Protocol Version 6.0 
 
 
6.1.1 Procedures 
 
Day 1 of each cycle 
 
Before administering TVB-2640, the following procedures will be done in all subjects, 
within 3 days of Cycle 1 Day 1: 
 
  Record interim medical history since screening; 
  Confirm that subject continues to meet inclusion/exclusion criteria; 
   Record concomitant medications for previous 14 days; 
   Draw serum and whole blood samples for analysis 
  A separate serum sampling will be drawn to analyze presence of Microvesicles (proteomic 
and lipidomic analysis) by standard centrifugation techniques. Only required within 3 days 
of C1D1 and within 3 days of C1D28. 
 
The following procedures will be done prior to TVB-2640/Bevacizumab administration within 3 
days prior to Cycle 1 Day 1 and within 3 days prior to Day 1 for All Future Cycles (unless 
otherwise specified): 
 
  Assess Eastern Cooperative Oncology Group (ECOG) Performance Status score 
  Assess whether subject is adequately hydrated for administration of study drugs 
  Cycle 2 and all subsequent cycles: Record AEs since last visit 
  Any skin or mucosal lesions considered due to TVB-2640 should be photographed and, if 
possible, also biopsied. 
  Record concomitant medications since last cycle; 
  Record weight and vital signs; 
  Detailed physical exam including neurologic assessment. 
  Draw blood samples for hematology and chemistry; 
  Obtain (serum or urine) pregnancy test in females of childbearing potential 
  Urine dipstick for protein and glucose. If positive and a change from baseline or 
previous cycle, complete urinalysis including microscopic analysis should be performed 
  Administer TVB-2640 (Plus or minus 2days.) 
  Administer bevacizumab (Plus or minus 2 days.) 
   Draw serum and whole blood samples for analysis 

Page 28 of 60 
Protocol Version 6.0 
 
 
 
Day 15 of each cycle 
  A physical exam will be done on Day l5 of Cycles 1 and 2. This may occur up to 
3 days prior to Day 15. 
  Physical exam on Day 15 for Cycle 3 and beyond will only be done if 
clinically indicated. If done, this may occur up to 3 days prior to Day 15. 
  Record concomitant medications drugs since the last visit. This may occur up to 
3 days prior to Day 15. 
  Record AEs since the last visit. This may occur up to 3 days prior to Day 15. 
  Measure and record vital signs (BP, HR, RR, temperature). This may occur up to 
3 days prior to Day 15. 
  Obtain blood samples for hematology, chemistry. This may occur up to 
3 days prior to Day 15. 
  Urine dipstick for protein and glucose. If positive and a change from baseline or 
previous cycle, complete urinalysis including microscopic analysis should be performed 
  Administer TVB-2640 (Plus or minus 2 days.) 
   Administer bevacizumab (Plus or minus 2 days.) 
 
6.2 Study Termination / Early Study Termination and Survival Follow up. 
 
6.2.1 Study Termination / Early Study Termination 
 
This visit will occur 3-4 weeks after the start of Cycle 6 or at least 2 weeks after the last dose of 
TVB-2640 treatment for subjects who terminate early. Subjects who have not progressed after 6 
cycles may be permitted to continue therapy on a case-by-case basis after discussion with the PI. 
The following will be done at the Termination/Early Termination visit: 
 
  Record concomitant medications, including vitamins, herbal preparations, blood products, 
and other OTC drugs since the last visit 
  Record AEs since the last visit 
  Perform a complete physical examination, including weight 
  Assess Eastern Cooperative Oncology Group (ECOG) Performance Status score 
  Measure and record vital signs (BP, HR, RR, temperature) 
  Obtain blood samples for hematology, chemistry and INR 
  Obtain serum and whole blood samples for biomarker analysis 
  Obtain urine sample for HCG HCG pregnancy test in female subjects of  child-bearing 
potential  (all  female  subjects  unless  surgically  sterilized  or  at  least   1   year  post- 
menopausal) 
  Obtain  a urine sample  for urinalysis 
  Perform tumor assessments, using the same imaging assessments done at baseline, if not 
done within past 4 weeks 
  Any ongoing study drug-related AE present at study termination, including a clinically 
significant laboratory test abnormality, will be followed until resolved or until the event 
stabilizes and the overall clinical outcome has been ascertained. 
 Adverse events starting up to 30 days after the last dose of study medication may be 
collected by telephone contacts. 

Page 29 of 60 
Protocol Version 6.0 
 
 
6.2.2 Survival Follow-up 
 
When a subject has completed the study termination or early termination visit, he/she and/or a 
family member will be contacted for survival information every 3 months until one year from first 
dose. Anti-tumor therapy (description and dates) since the last contact will be collected at each 
survival follow up. 
 
6.3 Assessment of Safety 
 
6.3.1 Physical Examination 
 
A complete physical examination will be performed at screening and at study termination or early 
study termination, results will be recorded by the investigator (or designee). Limited physical 
examination will be done on day 1 and 15 of each cycle until last visit throughout the study. Body 
weight will be measured on Day 1 of every cycle. The results of the physical examinations will be 
used for safety monitoring purposes only. At each study visit, according to good medical practice, 
the subject's general health (e.g., appearance, adequacy of hydration, presence of illness or injury, 
temperature, and vital signs indicative of a concurrent illness) will be assessed to determine 
whether continued dosing is appropriate. 
 
 
6.3.2 Vital Signs 
 
BP, HR, RR and temperature will be measured at the following time points: 
• 
Screening 
• 
Day 1 and Day 15 of every cycle (predose and postdose for each study drug administered) 
• 
Study Termination or Early Study Termination 
 
Blood pressure and HR measurements should be obtained with the subject's arm unconstrained by 
clothing or other material and supported at the level of the heart. The measurements will be 
obtained with the appropriate cuff size from the arm opposite that used for blood sampling. All 
BP measurements will be obtained from the same arm throughout the dosing period. The cuff 
should be placed on the designated arm at least 10 minutes prior to taking BP measurements. 
 
6.3.3 Chest X-Ray or Computed Tomography 
 
A chest X-ray or CT is to be performed during Screening within 28 days of Baseline. 
 
6.3.4 Electrocardiogram 
 
At Screening, 12-lead ECG will be performed for all patients at Baseline and at the Final Study 
visit. 
 
6.3.5 Hematology, Clinical Chemistry and Urinalysis 
 
Blood samples for hematology and clinical chemistry and urine samples for urinalysis are to be 

Page 30 of 60 
Protocol Version 6.0 
 
collected for all patients during Screening, up to 72 hours before scheduled clinic visits on Day 1, 
and 15 of every cycle; and at the Final Study Visit. 
 
Hematology and clinical chemistry results must be reviewed by the Investigator prior to study drug 
administration. If any clinically relevant hematology or clinical chemistry abnormalities are 
identified after the patient leaves the clinic, the patient is to be contacted and appropriate follow- 
up performed. 
 
Hematology 
CBC w/differential 
 
Coagulation Studies 
Prothrombin time (PT)/INR 
Activated partial thromboplastin time (aPTT) 
 
Chemistry 
Blood urea nitrogen (BUN) 
Creatinine 
Albumin 
Total protein 
ALT/AST 
Alkaline phosphatase (ALP) 
Total bilirubin 
Creatine phosphokinase (CPK) 
Carbon dioxide (C02) 
Chloride (Cl) 
Sodium (Na) 
Potassium (K) 
Calcium 
Magnesium 
Glucose 
 
Standard lipid panel (Screening only) 
(i.e., low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and total 
cholesterol) 
 
Urinalysis 
Specific gravity 
pH 
Blood 
Glucose 
Protein 
Ketones 
Microscopic examination of sediment 
 
Clinical laboratory evaluations are to be repeated as necessary during treatment at a schedule 
determined by the Investigator, based on the patient's clinical status. 

Page 31 of 60 
Protocol Version 6.0 
 
 
Laboratory abnormalities considered by the Investigator to be clinically significant during 
Screening and before study drug administration at Baseline are to be reported as part of the 
patient's medical history.  Clinically significant laboratory abnormalities occurring after the start 
of study drug will be reported as an AE when the finding represents a change from Baseline. 
 
6.3.6 Pregnancy Testing 
 
 
For women of child-bearing potential, a serum β-human chorionic gonadotropin (hCG) pregnancy 
test will be performed during Screening and a serum or urine β-hCG pregnancy test will be 
performed within 48 hours before Baseline, D 1 of each subsequent treatment cycle, and the Final 
Study Visit. 
The patient must agree to adequate birth control from the time the Screening pregnancy test is 
performed through 3 months after the final study drug dose. Study drug is to be discontinued for 
any patient with positive pregnancy test findings. 
 
6.3.7 Ophthalmologic Examinations 
 
Ophthalmologic examinations are to be performed during Screening, on D1 (+3 days) of C2, and 
and at the Final Study Visit. After C2D1, ophthalmologic examinations are to be repeated as 
clinically indicated. 
 
Near and far visual acuity is to be assessed by an ophthalmologist using standard measures (e.g., 
Early Treatment Diabetic Retinopathy Study (ETDRS) or similar) in each eye. If the patient wears 
corrective lenses (e.g., glasses), then visual acuity is to be checked first with corrective 
lenses and then without correction. (A best-corrected examination is not required.) Note that 
contact lens wearers are to abstain from contact lens use during study drug treatment (i.e., from 
Baseline through the final TVB-2640 dose). 
 
6.3.8 Disease Assessment 
 
Patients will be assessed at screening, within 3 days prior to Cycle 1 Day 1, and at the end of every 
even cycle, with MRI per the modified RANO criteria as detailed in Appendix B. 
 
7 
PHARMACEUTICAL INFORMATION 
 
7.1 Study Drug Supplies 
 
TVB-2640 is supplied by 3-V Biosciences, Inc. as 50 mg and 200 mg strength capsules. Additional 
formulations of TVB-2640 may be introduced, when available. The bevacizumab will be obtained 
by the study center through commercial supplies. 
 
7.2 Study Drug Packaging and Labeling 
 
TVB-2640 will be packaged in bulk, screw-top plastic bottles. TVB-2640 will be labeled in 
accordance with applicable regulatory requirements. Study drug labels will not bear any statement 

Page 32 of 60 
Protocol Version 6.0 
 
that is false or misleading in any manner or represents that the study drug is safe or effective for 
the purposes for which it is being investigated. 
 
Bevacizumab will be commercially packaged and labeled. 
 
 
7.3 Study Drug Storage 
 
TVB-2640 is to be stored at room temperature. Refer to the Investigator Brochurel for more 
detailed information regarding study drug storage. 
 
7.4 Study Drug Accountability 
 
The US Food and Drug Administration (FDA) and other applicable regulatory authorities require 
accounting of all investigational drug received by each study center. Records of drug disposition 
required include the date received by the center, date administered, quantity administered, and the 
patient to whom study drug was administered. The Investigator is responsible for the 
accountability of all used and unused study drug containers and unused study drug. The study 
center also will maintain records for bevacizumab distribution, including the date administered, 
quantity administered, and the patient to whom the agent was administered. 
 
The patient identification number and patient initials are to be recorded on each study drug 
accountability log. Each time study personnel dispense study drug for a patient, he or she is to 
record the date dispensed, amount of study drug dispensed, and his or her initials. Study personnel 
are to monitor the inventory of clinical supplies and maintain a count of all used and unused study 
drug. Pharmacy records will be reviewed during each audit performed by the QAU. 
 
7.5 Study Drug Dose and Administration 
 
Unless an alternate schedule is specified by the Sponsor, all patients are to receive TVB-2640 PO 
Continuously. For the purposes of this study, a treatment cycle is considered to be 28 days. The 
amount (in mg) of TVB-2640 to be administered initially is based on BSA, as calculated at Baseline 
and on Dl of every other cycle thereafter, starting with C3. As TVB-2640 is supplied as 50 mg and 
200 mg strength capsules, the actual dose administered was to be within -20 to + 15% of the 
calculated dose. The flat dose of TVB-2640 to be administered, based on the patient's BSA, is as 
follows: 
 
• BSA <1.5 m2 : TVB-2640 100 mg flat dose 
• BSA >l .5 and <2.0 m2 : TVB-2640 150 mg flat dose 
• BSA >2.0 and <2.5 m2 : TVB-2640 200 mg flat dose 
• BSA >2.5m2: TVB-2640 250 mg flat dose 
 
 
TVB-2640 initially will be administered on a QD schedule; thus, patients receiving TVB-2640 QD 
will receive 28 doses of TVB-2640 in each cycle. Each QD TVB-2640 dose is to be taken at the 
same time of the day under fasted conditions (i.e., at least 2 hours after last food consumption and 
at least 1 hour before next food consumption), with each dose separated by 24 hours (±4 hours). 

Page 33 of 60 
Protocol Version 6.0 
 
Bevacizumab will be administered as per the prescribing information or per institutional standard 
of care, with the dose regimen documented in the eCRF. Any required pre- or concurrent 
medication is also to be administered in accordance with the prescribing information and routine 
clinical practice. On study visit days when both TVB-2640 and bevacizumab are to be administered, 
TVB-2640 should be taken approximately 2 hours prior to the initiation of the anticancer agent 
administration. 
 
 
8    MANAGEMENT OF INTERCURRENT EVENTS 
 
Comprehensive assessments of any apparent toxicity experienced by the subject will be performed 
throughout the course of the study. Study site personnel will report any clinical AE, whether 
observed by the investigator or reported by the subject. 
 
8.1 Grading of Toxicity and Monitoring/Treatment of Toxicity 
 
Clinical AEs or abnormal laboratory test results will be assessed by the principal investigator or 
other designated other physician, in accordance with the CTCAE v 4.03 criteria. 
 
A physician or other qualified medical professional (e.g. Physician Assistant, Nurse Practitioner) 
designated by the Principal Investigator will manage and treat any toxicity. Subjects should  be 
referred to an ophthalmologist for evaluation if clinically significant ophthalmologic abnormalities 
are noted. The ophthalmologist should be directed to perform examinations as clinically indicated. 
 
8.2 Adverse Events 
 
The most common (i.e., Incidence ≥10%) adverse events of any grade considered possibly, 
probably or definitely related to TVB-2640 among patients treated with TVB-2640 monotherapy 
were as detailed below and should be considered in the evaluation of patients. Given the non- 
overlapping toxicity profile with bevacizumab, it is expected that the toxicity profile of the 
combination should be similar to those of the individual agents. A physician or other qualified 
medical professional (e.g. Physician Assistant, Nurse Practitioner) designated by the Principal 
Investigator will assess  the  seriousness,  severity,  and  causality  of  an  AE  based  on  the 
following definitions. 

Page 34 of 60 
Protocol Version 6.0 
 
 
 
 
8.2.1 Defining Adverse Events 
 
An adverse event (AE) is any undesirable event occurring to or in a subject enrolled in a clinical 
trial, whether or not the event is considered related to the study drugs (TVB-2640, &/or 
bevacizumab). This includes the time periods beginning after the  first  administration  of  study 
drug until  30  days  after the last  dose of study drug. 
 
 
Adverse events include the following types of occurrences: 
1) Suspected adverse reactions; 

Page 35 of 60 
Protocol Version 6.0 
 
2)  Other medical experiences, regardless of their relationship to the study drug, such as injury, 
causes for surgery, accidents, increased severity of pre-existing symptoms, apparently unrelated 
illnesses, and significant abnormalities in clinical laboratory values, physiological testing, or 
physical examination findings; and 
 
3) Reactions from drug overdose, abuse, withdrawal, sensitivity, or toxicity. 
 
8.2.1.1 Serious Adverse Events 
 
A serious adverse event (SAE) is any adverse' experience that occurs at any dose and results in 
any of the following outcomes. 
 
1)  Death. This includes any death that occurs during the conduct of the clinical study, including 
deaths that appear to be completely unrelated to the study drug (e.g., car accident). However, 
deaths that occur due to disease progression are not considered SAEs, but should be reported as a 
death on study. If a subject dies during the study, and an autopsy is performed, the autopsy results 
should be sent to 3-V Biosciences. Possible evidence of organ toxicity and the potential 
relationship of the toxicity to the study drug are of particular interest. The autopsy report should 
distinguish between the relationship between the underlying diseases, their side effects, and the 
cause of death. 
 
2)  Life-threatening adverse experience. This includes any AE during which the subject is, in the 
view of the investigator, at immediate risk of death from the event as it occurs. This definition 
does not include any event that may have caused death if it had occurred in a more severe form. 
 
3)  Persistent or significant disability or incapacity. 
 
4)  Inpatient hospitalization or prolongation of existing hospitalization. 
 
5)  Congenital anomaly or birth defect. 
 
6) Other medically important event which, according to appropriate medical judgment, may 
require medical or surgical intervention to prevent one of the outcomes listed above. 
 
7) Pregnancy occurring in subjects treated with TVB-2640 should be reported using the serious 
adverse event reporting form (MedWatch form can be used for reporting). 
 
8.2.1.2   Nonserious adverse events 
 
A nonserious AE includes any AE that is not defined as an SAE. 
 
8.2.1.3   Unexpected adverse events 
 
 
An unexpected AE is any AE that is not identified in nature, severity or frequency. 
 
8.2.2  Documenting All Adverse Events 

Page 36 of 60 
Protocol Version 6.0 
 
 
Record all AEs as descriptive findings (symptoms, or laboratory, physical exam, or vitals 
abnormalities) or diagnoses if etiology is known. Included are all AEs that occur after the start of 
treatment or within 30 days of administration of the last dose of study drug. Record AEs of any 
severity and AEs that are assessed as serious or not serious. 
 
Note: Unchanged, chronic conditions and cancer symptoms present at baseline are NOT AEs and 
should not be recorded unless there is an exacerbation or worsening in severity of a chronic 
condition or cancer symptom  after the first  administration of study drug until 30 days after the 
last dose of study drug.  Chronic conditions and/or cancer symptoms that exacerbate or worsen in 
severity should be documented as a "worsening" condition. Death due to disease progression and 
measures of disease progression collected as efficacy endpoints (eg: increasing tumor size or new 
lesions) are not considered adverse events, but should be collected as termination reasons (if 
applicable) and/or noted in tumor assessment appropriate. Other reasons for death occurring during 
the AE reporting period are SAEs and should be reported as such. 
 
8.2.2.1 Grading of Adverse Events 
 
Severity of AEs or clinically significant laboratory test results will be assessed in accordance with 
the grading scale presented in the Common Terminology Criteria for Adverse Events (CTCAE) 
version  4.03.  A  copy  of  this  document  can  be  found  at  the  following  internet  site: 
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. 
Clinically significant abnormal laboratory results and lab results requiring an intervention will be 
recorded as AEs and should describe whether the lab result was increased or decreased. The 
following definitions for rating severity of AEs will be used for events not covered in the CTCAE. 
 
Grade 1: Mild; awareness of signs or symptoms that are easily tolerated, are of minor irritant type, 
cause no loss of time from usual activities, do not require medication or further medical evaluation, 
and/or are transient. 
 
Grade 2: Moderate; signs or symptoms sufficient to interfere with function but not activities of 
daily living. 
 
Grade 3: Severe; signs or symptoms sufficient to interfere with activities of daily living; signs and 
symptoms may be of a systemic nature, or require further medical evaluation and/or treatment. 
 
Grade 4: Disabling or with life-threatening consequences. (This definition does not include any 
event that might have caused death if it had occurred in a more severe form.) 
 
Grade 5: Death 
 
 
8.2.2.2 Relationship to Study Drug 
 
The causal relationship of each AE to study drug will be determined by the Investigator according 
to best medical judgment, as follows: 

Page 37 of 60 
Protocol Version 6.0 
 
Definitely related: This category applies when, after careful medical consideration, there is almost 
no consideration of other causation. 
 
Probably related: There is a clinically plausible time sequence between onset of the AE and study 
drug administration. The AE is unlikely to be caused by a concurrent and/or under lying illness, 
other drugs, or procedures. If applicable, the AE follows a clinically consistent resolution pattern 
upon withdrawal of study drug. 
 
Possibly related: There is a clinically plausible time sequence between onset of the AE and study 
drug administration, but the AE could also have been caused by the concurrent/underlying illness, 
other drugs, or procedures. Information regarding study drug withdrawal may be lacking or 
unclear. "Possible" should be used when study drug administration is one of several biologically 
plausible causes of the AE. 
 
Unlikely related: The AE is most likely due to a non-study drug-related cause. However, 
association with the study drug cannot be completely ruled out. 
 
Unrelated: Another cause of the AE is most plausible and a clinically plausible temporal sequence 
is inconsistent with the onset of the AE and study drug administration and/or a causal relationship 
is considered biologically implausible. 
 
If the relationship between the AE/SAE and study drug is determined to be "possible", ''probable", 
or "definite", the event will be considered to be treatment-related for the purposes of expedited 
regulatory reporting and safety analyses. 
 
8.2.2.3 Abnormal Laboratory Test Results as Adverse Events 
 
The investigator will monitor the laboratory test results and determine the clinical significance of 
any result that falls outside of the reference range. In accordance with good medical practice, any 
clinically significant abnormal laboratory test results must be followed until resolved or stabilized. 
Abnormal laboratory test results should not be reported as AEs unless, in the opinion of the 
investigator, the results constitute or are associated with a clinically relevant condition or require 
intervention. 
 
In the event of unexplained, clinically significant abnormal laboratory test results, the tests should 
be repeated immediately and followed up until the values have returned to within the reference 
range or to baseline for that subject. 
 
8.2.3  Reporting and Documenting Serious Adverse Events 
Serious adverse events (SAE) that occur at any time point after the first dose of study drug until 
30 days after the last dose of study drug must be reported. SAEs must be reported as per 
institutional policy and as required under the Data Safety Monitoring Plan (see Section 11.6 for 
DSMP). 
 
1) Submit all known subject information (listed below) within 24 hours of knowledge of the SAE 
occurrence. The following information should also be entered in the database (or as much as 

Page 38 of 60 
Protocol Version 6.0 
 
possible to obtain and still report the event within 24 hours): 
 
a)   Subject's Demographic Data 
b)   Subject's weight 
c)   Description of SAE, including date of onset and duration, severity, and outcome 
d)  All dosing data of study drugs administered up to the date the SAE occurred 
e)  Action taken regarding study drug administration 
f)   Relationship of SAE to study drugs 
g) Concomitant medications, including regimen and indication 
 
h)  Intervention, including concomitant medications used to treat SAE 
 
i)   Pertinent laboratory data and diagnostic tests conducted and date 
j)   Pertinent medical history of subject 
k)  Date of hospital admission discharge (if applicable) 
 
i)  Date of death (if applicable) 
 
2)  Perform appropriate diagnostic tests and therapeutic measures, and submit all follow-up 
substantiating data, such as diagnostic test reports and autopsy report to 3-V Biosciences. 
 
3)  Conduct appropriate consultation and follow-up evaluations until the events are resolved, 
stabilized, or otherwise explained by the principal investigator. 
 
4)  Review each SAE report and evaluate the relationship of the SAE to study treatment and to the 
underlying disease. The Investigator Brochure developed by 3-V Biosciences will be used to 
determine whether the SAE is unexpected in nature. 
 
5) Based on a cooperative assessment of the SAE with 3-V Biosciences, a decision for any further 
action will be made. The primary consideration is subject safety. If the discovery of a new SAE 
related to the study drug raises concern over the safety of its continued administration to subjects, 
3-V Biosciences will be notified first, subsequent notification to the FDA will be generated by the 
PI and 3-V Biosciences. 
 
6) The investigator must report all SAEs and unexpected problems promptly to the IRB/IEC, 
as appropriate (see ICH Guidelines, Good Clinical Practice (E6)). 
 
Other actions regarding SAEs might include the following: 

Page 39 of 60 
Protocol Version 6.0 
 
 
a) Protocol amendment 
 
b) Discontinuation or suspension of the protocol 
 
c) Modification of informed consent to include recent findings 
d) Informing current study participants of new findings 
e) Identification of specific AEs as drug-related 
 
8.2.4  Follow Up of Adverse Events 
 
All AEs are followed until they are resolved or determined to be irreversible or otherwise explained 
by the principal investigator. 
 
8.3 
Concomitant and Excluded Therapy 
 
All medications and blood products (prescription and over-the-counter including herbal 
preparations) taken within 14 days of Cycle l/Day 1 will be recorded by the investigator (or 
designee). The reason(s) for treatment, dosage, and dates of treatment should be recorded in the 
source documents. In addition, concomitant medications used to treat adverse events occurring up 
to 30 days after the last dose of study drug will be recorded. 
 
Female subjects who have been on hormone replacement therapy (HRT) for menopausal 
symptoms for a period of at least 2 months will not be excluded from the study provided the HRT 
regimen remains unchanged during the conduct of the study. 
 
 
9    REMOVING SUBJECTS FROM THE STUDY 
 
9.1 Criteria for Termination 
 
Subjects are free to discontinue (withdraw) at any time during this clinical trial. If a subject 
withdraws from participation in the study during the treatment period, he or she should be 
encouraged to return for an early termination visit for evaluation of safety (see Section 6.2.1, Study 
Termination/Early Study Termination). 
The investigator has the right to discontinue any subject from study drug administration or  study 
participation. Reasons for subject discontinuation may include, but are not limited to, the 
following: 
 
• Clinically significant deterioration of the subject’s condition; 
 
• Disease  progression; 
 
• Requirement for other anti-tumor therapy during the study; Noncompliance; 
 
• Pregnancy; Significant AE; 

Page 40 of 60 
Protocol Version 6.0 
 
• Subject's right to withdraw from the study at any time, with or without stated reason; 
 
• Significant protocol violation; 
 
• Lost to follow-up; 
 
• Death; 
 
 
Any other reason that, in the opinion of the principal investigator, would justify the removal of a 
subject from the study. The primary consideration in any determination to discontinue a subject's 
participation must be the health and welfare of the subject. 
 
All subjects will be instructed on the importance of complying with the requirements of the study. 
It is expected that subjects will complete all of the necessary visits. If a subject does not return for 
follow-up visits as directed or does not adhere to the study requirements, the investigator will 
determine if early withdrawal should occur. 
 
9.2 Documentation 
 
The primary reason for early removal of a subject from the study must be documented clearly, and 
must be completed for any subject who has received any amount of drug during the treatment 
period. If the  reason for early withdrawal is an AE or an abnormal laboratory value, the specific 
event or test result must also be recorded. 
 
9.3 For Participants who withdraw early 
Following early termination, the subject should be informed about which evaluations are necessary 
to monitor his or her safety. In addition, subjects should be encouraged to complete any procedures 
or evaluations outlined in Section 6.2.1 Study Termination/Early Study Termination. 
 
9.4 Replacement of Subjects 
 
Subjects who have not received TVB-2640 will be replaced. Subject enrollment numbers are 
unique and will not be re-assigned. 
 
10  CONDITIONS FOR INITIATING, MODIFYING, OR TERMINATING THE STUDY 
 
10.1 
Institution Review 
 
The investigator will submit this protocol, any protocol modifications, and the subject consent 
form to be used in this study to the local Institutional Review Board (IRB) for review and approval. 
 
10.2 Informed Consent 
 
The investigator or his or her designee must explain to the subject, in the presence of a   witness, 
the purpose and  nature  of the study,  the study procedures,  and  the possible adverse effects, 
and all other elements of  consent  as  defined  in  21  CFR  Part  50  and  Clinical Trial Directive 
or ICH E6 guidelines before enrolling that subject in the study.   It           is the investigator's (or 

Page 41 of 60 
Protocol Version 6.0 
 
designee's) responsibility to obtain informed written consent from each subject, or if appropriate, 
the subject's parent or legal guardian. 
 
10.3 Modifications 
 
If any modifications in the experimental design, dosages, parameters, subject selection, or any 
other sections of the protocol are indicated or required, the investigator will consult with 3-V 
Biosciences  before  such  changes  are  instituted.  Modifications will be accomplished through 
formal amendments and approval from the appropriate IRB. 
 
10.4 Deviations 
 
The PI will consider any deviations from the protocol on a case by case basis. The investigator or 
other designated alternate in his absence will contact the local DSMB (DSMB2) as soon as possible 
to discuss the associated circumstances. The principal investigator and the DSMB will then decide 
whether the subject should continue to participate in the study. All protocol deviations and the 
reasons for such deviations must be noted in the source documents and will be reported to the Mays 
Cancer Center DSMC and to the IRB as per standard institutional policy. 
 
 
10.5 Termination 
 
The investigator reserves the right to terminate the study at any time. If the investigator discovers 
conditions arising during the study that suggest the study should be halted, he will alert the DSMB and 
the local IRB. Conditions that may warrant study or study center termination include, but are not 
limited to: 
• The discovery of any unexpected, significant, or unacceptable risk to the patients 
enrolled in the study. 
• Failure of the Investigator to enter patients at an acceptable rate. 
• Insufficient adherence to the protocol requirements. 
 
Should the study be closed prematurely, all study materials (study drug, etc.) must be returned to 
3V biosciences or designee (or disposed of as directed by the 3VB or designee). 
 
11  INVESTIGATOR'S RESPONSIBILITIES 
 
11.1 
Responsibilities / Performance 
 
The investigator will ensure that this study is conducted in accordance with all regulations 
governing the protection of human subjects. The investigator will adhere to the basic principles of 
"Good Clinical Practice," as outlined in Title 21 of the Code of Federal Regulations (CFR), Part 
312, Subpart D, "Responsibilities of Sponsors and Investigators"; 21 CFR, Part 50, "Protection of 
Human Subjects"; 21 CFR, Part 56, "Institutional Review Boards"; and the US Food and Drug 
Administration (FDA) guideline entitled "Good Clinical Practice: Consolidated Guideline". For 
studies conducted outside of the USA, the investigator will ensure adherence to the principles 
outlined in the International Conference on Harmonization (ICH) E6 "Guideline for Good Clinical 
Practice". Additionally, this study will be conducted in compliance with the Declaration of 
Helsinki and with any local laws and regulations of the country in which the research is conducted. 

Page 42 of 60 
Protocol Version 6.0 
 
The investigator will ensure that all work and services described in or          associated with this 
protocol will be conducted in accordance with the investigational plan, applicable regulations, and 
the highest standards of medical and  clinical  research  practice.  The investigator is responsible 
for the control of drugs under investigation.  The investigator will provide copies of the study 
protocol and Investigator's  Brochure  to  all  sub-investigators, pharmacists, and other staff 
responsible for study conduct. 
 
11.2 Confidentiality 
 
The investigator must ensure that each subject's anonymity will be maintained and each subject's 
identity will be protected from unauthorized parties. A number will be assigned to each subject 
upon study entry and the number and the subject's initials will be used to identify the subject for 
the duration of the study. Documents submitted to 3-V Biosciences should not identify a subject 
by name. Documents that are not submitted to 3-V Biosciences (eg, signed consent form) will be 
maintained by the investigator in strict confidence. 
 
11.3 Institutional Review 
The investigator will submit this protocol, any protocol modifications, and any accompanying 
material provided to the subject (eg, informed   consent  form,  subject   information sheets, or 
descriptions of the  study used to obtain informed consent) to the appropriate IRB for review and 
approval. A letter confirming IRB approval of the protocol and subject consent forms, and an IRB 
approved informed consent form must be forwarded to 3-V Biosciences prior to the enrollment of 
subjects into the study. A copy of the approved subject consent form will also be forwarded to 3-V 
Biosciences. 
 
11.3.1 Modifications 
 
If any modifications in the experimental  design,  dosages,  parameters,  or  subject  selection  are 
indicated or required, the investigator will consult with 3-V Biosciences (or vice versa) before 
such changes are instituted. Modifications will be accomplished through formal amendments to 
this protocol and approval by the appropriate IRB. Copies of all subsequent IRB approvals (e.g., 
protocol amendments) must be sent to 3-V Biosciences. 
 
11.3.2 Protocol Deviations 
 
The PI will consider any deviations from the protocol on a case-by-case basis. The investigator or 
other designated alternate in his absence will contact the local DSMB (DSMB2) as soon as 
possible to discuss the associated circumstances. The principal investigator and the DSMB will 
then decide whether the subject should continue to participate in the study. All protocol deviations 
and the reasons for such deviations must be noted in the source documents and will be reported to 
the Mays Cancer Center DSMC and the IRB as per standard institutional policy. 
 
11.3.3 Termination 
 
If 3-V Biosciences and/or the investigator(s) discover conditions during the course of the study 
that indicate it should be discontinued, an appropriate procedure for terminating the study will 

Page 43 of 60 
Protocol Version 6.0 
 
be instituted, including notification of the appropriate regulatory agencies and the IRB. 
 
11.4  Informed Consent and permission to use protected Health Information 
 
It is the responsibility of the investigator to obtain written informed consent from each subject 
participating in this study after adequate explanation, in lay language, of the methods, objectives, 
anticipated benefits, and potential hazards of the study.  The investigator must also explain that 
the subject is completely free to refuse to enter the study or to discontinue participation at any time 
(for any reason) and receive alternative conventional therapy as indicated. Prior to study 
participation, each  subject will sign an IRB approved informed consent form, and receive a copy 
of same. For participant subjects not qualified or able to give legal consent, consent must be 
obtained from a parent, legal guardian, or custodian. 
 
The investigator or designee must explain to the subject before enrollment into the study that for 
valuation of study results, the subject’s protected health information obtained during the  study 
may be shared with 3-V Biosciences, regulatory agencies, and IECs/IRBs. It is the investigator's 
(or designee's) responsibility to obtain permission to use protected health information per HIPAA 
from each subject, or if appropriate, the subjects' parent or legal guardian. 
 
11.5  Source Documentation and Investigator Files 
 
The investigator must maintain adequate and accurate records to fully document the conduct     of 
the study and to ensure that study data can be subsequently verified. These documents should be 
classified into 2 separate categories: (1) investigator study file and (2) subject clinical source 
documents that corroborate data collected. 
 
Subject clinical source documents would include hospital clinic patient records;  physician's 
and nurse's notes; appointment book; original laboratory, ECG, EEG,  radiology, pathology, 
and special assessment reports; pharmacy dispensing records; subject diaries; signed informed 
consent forms; consultant letters; and subject screening and enrollment logs. 
 
The following will be documented in source documents at the site: 
 
1) 
Medical history/physical condition and diagnosis of the subject before involvement in the 
study sufficient to verify protocol entry criteria (if not already present); 
 
2) Study number, assigned subject number, and verification that written informed consent was 
obtained (each recorded in dated and signed notes on the day of entry into the study); 
 
3)  Progress notes for each subject visit (each dated and signed); 
 
4)  Study drug dispensing and return; 
 
5)  Review of laboratory test results; 
 
6)  Adverse events (action taken and resolution); 

Page 44 of 60 
Protocol Version 6.0 
 
 
7)  Concomitant medications (including start and stop dates); and 
 
8)  Condition of subject upon completion of or early termination from the study. 
 
11.5.1 Exclusion Log 
 
The investigator must keep a record listing all patients considered for entry into the study but 
subsequently excluded. The reason for each exclusion will be recorded in the Subject Exclusion 
Log. 
 
11.6   Data Safety Monitoring Plan 
 
 
A Data and Safety Monitoring Plan is required for all an individual protocols conducted at Mays 
Cancer Center. All protocols conducted at UT Health Cancer Center are covered under the 
auspices of the Mays Cancer Center Institutional Data Safety Monitoring Plan (DSMP). 
 
The MaysCancer Center Institutional DSMP global policies provide individual trials with: 
 
• Institutional policies and procedures for institutional data safety and monitoring 
• An institutional guide to follow 
• Monitoring of protocol accrual by the Mays Cancer Center Protocol Review Committee 
• Review of study forms and orders by the Forms Committee 
• Independent monitoring and source data verification by the Mays Cancer Center QA 
Monitor/Auditor tools for monitoring safety events 
• Monitoring of UPIRSO’s by the Director of Quality Assurance and DSMC 
• Determining level of risk (Priority of Audit Level Score – PALS) 
• Oversight by the Data Safety Monitoring Committee (DSMC), and verification of protocol 
adherence via annual audit for all Investigator Initiated Studies by the Mays Cancer Center 
Quality Assurance Division. 
 
11.6.1 Monitoring Safety 
 
Due to the risks associated with participation in this protocol, the Mays Cancer Center DSMB2 in 
conjunction with the Principal Investigator will perform assessment of adverse events, adverse 
event trends and treatment effects on this study. The Mays Cancer Center DSMB2 acts as an 
independent Data Safety Monitoring Board (DSMB) for IIS conducted at Mays Cancer Center. 
The Mays Cancer Center will monitor data throughout the duration of a study to determine if 
continuation of the study is appropriate scientifically and ethically. An additional layer of review 
is provided by the Mays Cancer Center Data Safety Monitoring Committee (DSMC) who will 
review the DSMB’s quarterly reports. 
 
Baseline events and adverse events will be captured using the Mays Cancer Center Master Adverse 
Events Document for each patient using CTCAE V4.0 for the grading and attribution of adverse 
events. Usage of the Mays Cancer Center Master Adverse Events Document centrally documents: 

Page 45 of 60 
Protocol Version 6.0 
 
• the event and grades the seriousness of the event, 
• if the event was a change from baseline, 
• the determination of the relationship between the event and study intervention, 
• if the event was part of the normal disease process, and 
• actions that were taken as a result of the event. 
 
11.6.2 Reporting Requirements 
 
For this study, the Master Adverse Events Documents collected on patients for this protocol will 
be reviewed by the Principal Investigator on a monthly basis to determine if a serious safety 
problem has emerged that result in a change or early termination of a protocol such as: 
 
 
• Dose modification, 
• Suspending enrollment due to safety or efficacy, or 
• Termination of the study due to a significant change in risks or benefits. 
 
The PI will provide the DSMB2 with the quarterly findings for discussion and review during their 
meetings. 
 
Specific areas of concern that will be reported to the DSMB2 regarding this study that would 
qualify as an endpoint are: 
 
• Evidence from metabolic change analysis of tumor tissue by MR-Spectroscopy and serum 
metabolomic changes  that TVB-2640 does in fact NOT penetrate the blood brain barrier 
and as such would have no therapeutic benefit to patients on study 
• Unacceptable toxicity that would prevent patients from receiving treatment and therefore 
benefit 
 
 
 
As per the Mays Cancer Center DSMP, any protocol modifications, problematic safety reports, 
unanticipated problems, and suspension or early termination of a trial must be reported to all 
members of the research team. Suspension and early termination of a trial must also be reported 
immediately to the Director of Quality Assurance who will promptly notify the sponsor and the 
UTHSCSA IRB. 
 
The PI will review the Master Adverse Events documents to determine the significance of the 
reported events and will provide findings using the Investigator Initiated Study Quarterly DSMC 
Report Form.. The DSMB2 will review the information provided by the PI and report to the Mays 
Cancer Center DSMC on a quarterly basis unless an emergent issue has been identified. The 
Investigator Initiated Study Quarterly DSMC Report Form includes information on adverse events, 
current dose levels, number of patients enrolled, significant toxicities per the protocol, patient 
status (morbidity and mortality) dose adjustments with observed response, and any interim 
findings. Any trend consisting of three or more of the same event will be reported to the Mays 
Cancer Center DSMC for independent review outside of the quarterly reporting cycle, which 
begins three months following protocol start up. The DSMB2 will also provide its findings to the 

Page 46 of 60 
Protocol Version 6.0 
 
Mays Cancer Center’s Regulatory Affairs Division so that it may be provided to the UTHSCSA 
IRB with the protocol’s annual progress report. Conflict of interest is avoided by the independent 
reviews of the Mays Cancer Center DSMB2, UT Health Cancer Center DSMC and by ongoing 
independent review of UPIRSO’s by the Director of Quality Assurance. 
 
All  SAE  and  UPRISO’s  will  be  reported  following  Mays  Cancer  Center  and  UTHSCSA 
institutional guidelines. 3-V Biosciences will be notified as well. 
 
UTHSCSA SAE/UPIRSO REPORTING REQUIREMENTS 
Type Event 
Report to 
Timeframe 
All AE, SAE and 
UPIRSO 
Regulatory affairs 
and DQA 
Per institutional 
requirements as noted 
below. 
SAE 
PI 
Within 24 hours 
AE/SAE 
UTHSCSA IRB 
Annually 
UPIRSO - All 
PI 
Within 24 hours of the PI 
determining a UPIRSO 
exists 
UPIRSO - life 
threatening 
UTHSCSA IRB 
Within 48 hours of the PI 
determining a UPIRSO 
exists 
UPIRSO - non- 
life threatening 
UTHSCSA IRB 
Within 7 days of the PI 
determining a UPIRSO 
exists 
 
 
Serious adverse events on NCI sponsored trials utilizing a commercially available agent (with no 
IND’s involved) will additionally be reported via the FDA’s Medwatch program. 
 
11.6.3 Assuring Compliance with Protocol and Data Accuracy 
 
As with all studies conducted at Mays Cancer Center, the PI has ultimate responsibility for 
ensuring protocol compliance and data accuracy/integrity. Protocol compliance, data accuracy and 
reporting of events is further ensured by an annual audit conducted by the Data Safety Officer, 
whose audit report is shared with the PI, the research team and will be reviewed by the Mays 
Cancer Center DSMC. 
 
Mays Cancer Center DSMB Membership 
 
 
The Mays Cancer Center has two DSMB’s with a primary set of members specific to the histology 
of the study consisting of UTHSCSA faculty and staff. This Protocol will utilize DSMB#2 for 
Solid Tumor Studies. 
 
As per NCI guidelines and to eliminate conflict of interest (financial, intellectual, professional, or 

Page 47 of 60 
Protocol Version 6.0 
 
regulatory in nature), the Mays Cancer Center DSMB specific to this study will not treat patients 
on this protocol. Usage of the DSMB specific to the histology has been created to ensure that 
experts in that histology are represented on the DSMB assembled for this protocol, but may be 
expanded, at the PI’s discretion, to include other members which may include: 
 
 
• Experts in the fields of medicine and science that are applicable to the study (if not currently 
represented on the DSMB), 
• Statistical experts, 
• Lay representatives, 
• Multidisciplinary representation, from relevant specialties including experts such as 
bioethicists, biostatisticians and basic scientists, and 
• Others who can offer an unbiased assessment of the study progress. 
 
Additional or alternate membership of in the DSMB is selected by the DSMC chair, in conjunction 
with the PI of this protocol. 
 
Mays Cancer Center DSMB Charter and Responsibilities 
 
The Mays Cancer Center DSMB will provide information on the membership composition, 
including qualifications and experience to both the UTHSCSA IRB and Mays Cancer Center PRC 
for review. The Mays Cancer Center DSMB for this study will act as an independent advisory board 
to the PI and will report its findings and recommendations to the PI, the UTHSCSA IRB and the 
Mays Cancer Center DSMC.  Mays Cancer Center DSMB reports will utilize the Investigator 
Initiated Study Quarterly DSMC Report Form and meetings will occur quarterly to review any 
updates from the prior meeting. 
 
Once the protocol is activated, if not already established elsewhere in the protocol the Mays Cancer 
Center DSMB will establish and provide: 
 
• procedures for maintaining confidentiality; 
• statistical procedures including monitoring guidelines, which will be used to monitor the 
identified primary, secondary, and safety outcome variables; 
• consider factors external to the study when relevant information becomes available, such 
as scientific or therapeutic developments that may have an impact on the safety of the 
participants or the ethics of the study; 
• plans for changing frequency of interim analysis as well as procedures for recommending 
protocol changes; 
• recommendation of dose escalation, MTD recommendation of early termination based on 
efficacy results; 
• recommendation of termination due to unfavorable benefit-to-risk or inability to answer 
study questions; 
• recommendation of continuation of ongoing studies; 
• recommend modification of sample sizes based on ongoing assessment of event rates; and 
• review of final results and publications. 

Page 48 of 60 
Protocol Version 6.0 
 
12  STATISTICAL CONSIDERATIONS 
 
This is a prospective, randomized, phase 2 study of TVB-2640 in combination with bevacizumab 
or bevacizumab alone in patients in first relapsed high grade astrocytoma. Analysis will be intent- 
to-treat of all randomized patients. 
 
 
Evaluability – Patients will be evaluable for inclusion in the analysis of the EFS comparison 
between treatment arms if they are randomized. 
 
The median time to progression of patients treated with Bevacizumab is 124 days (95% confidence 
interval: 87–154 days)(2).  A sample size of total 24 evaluable patients will be enrolled. 
 
• Study Design / End Points Primary outcome/endpoint: 
We will measure progression-free survival of patients with High Grade Astrocytoma who are 
treated with TVB-2640 in combination with bevacizumab versus bevacizumab alone, defined 
as time from study enrollment to the first occurrence of relapse, death from any cause or until 
last contact (if no event occurs) 
 
• Secondary outcomes/endpoints: 
We will evaluate and grade Incidence of adverse events as assessed by NCI CTCAE v. 4.03 
 
• Analytic plan for primary objective: 
We will test that the combination of bevacizumab and TVB-2640 versus bevacizumab alone 
will increase the rate of PFS, by using a non parametric test (Log-Rank), for a given alpha of 
0.1 and power of 91.6%. 
 
• Analytic plan for secondary objectives: 
Toxicities will be tabulated by type and grade according to NCI CTCAE v. 4.03 
 
12.2 Sample Size / Accrual rate 
 
A sample size of total 24 evaluable patients (enrolled within 1 – 1.5 years) will provide 91.6% 
power to detect a 4 month difference in the median time to progression (3 months for bevacizumab 
alone versus 7 months in TVB-2640 in combination with bevacizumab, i.e., a hazard ratio of 0.43) 
using a one-sided log-rank test with alpha=0.1. 
 
We expect to accrue 1 to 2 patients a month, i.e. about 12-24 patients per year. The 24 patients can 
be enrolled in 1 – 1.5 years. With an additional 3 months of follow-up on the last patient, the total 
study duration is about 18 months. 
The primary efficacy analyses for estimation of PFS rates will be performed using a one sided log- 
rank test for an overall type-I error at 0.1 for each treatment group and a power of 91.6%. Thus far 
we will be able to reject the null hypothesis that the experimental and control survival curves are 
equal. 

Page 49 of 60 
Protocol Version 6.0 
 
13. REFERENCES 
 
1. 
Rémy C, Fouilhé N, Barba I, Sam-Laï E, Lahrech H, Cucurella M-G, Izquierdo M, Moreno 
A, Ziegler A, Massarelli R. Evidence that mobile lipids detected in rat brain glioma by 1H 
nuclear magnetic resonance correspond to lipid droplets. Cancer research. 1997;57(3):407- 
14. 
2. 
Quant,E. et al, Role of a second chemotherapy in recurrent malignant glioma patientswho 
progress on bevacizumab. Neuro Oncol. 2009 Oct;11(5):550-5. doi: 10.1215/15228517- 
2009-006. Epub 2009 Mar 30. 
3.         Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: 
standard of care and future directions. J Clin Oncol. 2007;25(26):4127-36. Epub 2007/09/11. doi: 
25/26/4127 (pii) 10.1200/JCO.2007.11.8554 (doi). PubMed PMID: 17827463. 
 
4.         Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, 
Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, 
Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and 
adjuvant   temozolomide   for   glioblastoma.   The   New   England   journal   of   medicine. 
2005;352(10):987-96.   Epub   2005/03/11.   doi:   10.1056/NEJMoa043330.   PubMed   PMID: 
15758009. 
5.         Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis 
in brain tumours. Nat Rev Neurosci. 2007;8(8):610-22. Epub 2007/07/24. doi: nrn2175 
(pii)10.1038/nrn2175 (doi). PubMed PMID: 17643088. 
 
6.         Mercurio AM, Bachelder RE, Bates RC, Chung J. Autocrine signaling in carcinoma: 
VEGF and the alpha6beta4 integrin. Semin Cancer Biol. 2004;14(2):115-22. Epub 2004/03/17. 
doi:   10.1016/j.semcancer.2003.09.016   (doi)S1044579X0300083X   (pii).   PubMed   PMID: 
15018895. 
 
7.         Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes 
encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma 
multiforme. J Pathol. 2005;207(2):224-31. Epub 2005/07/16. doi: 10.1002/path.1823 (doi). 
PubMed PMID: 16021678. 
8.         Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, 
Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab 
plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England journal of 
medicine. 2014;370(8):709-22. Epub 2014/02/21. doi: 10.1056/NEJMoa1308345. PubMed PMID: 
24552318. 
9.         Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, 
Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber 
VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, 
Jr., Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New 
England      journal      of      medicine.      2014;370(8):699-708.      Epub      2014/02/21.      doi: 
10.1056/NEJMoa1308573. PubMed PMID: 24552317; PMCID: Pmc4201043. 

Page 50 of 60 
Protocol Version 6.0 
 
 
10. 
Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the 
temozolomide  era.  Journal  of  neuro-oncology.  2012;107(2):359-64.  Epub  2011/11/03.  doi: 
10.1007/s11060-011-0749-4. PubMed PMID: 22045118. 
 
11.       Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. 
Jama. 2013;310(17):1842-50. Epub 2013/11/07. doi: 10.1001/jama.2013.280319. PubMed PMID: 
24193082. 
 
12.       Lau D, Magill ST, Aghi MK. Molecularly targeted therapies for recurrent glioblastoma: 
current  and  future  targets.  Neurosurgical  focus.  2014;37(6):E15.  Epub  2014/12/02.  doi: 
10.3171/2014.9.focus14519. PubMed PMID: 25434384. 
 
13.       Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to 
targeted   treatment.   Annual   review   of   pathology.   2014;9:1-25.   Epub   2013/08/14.   doi: 
10.1146/annurev-pathol-011110-130324. PubMed PMID: 23937436. 
 
14.       Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, 
Kaur B, Van Meir EG. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix 
proteases, and are formed by an actively migrating cell population. Cancer Res. 2004;64(3):920- 
7. Epub 2004/02/12. PubMed PMID: 14871821. 
 
15.       Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, 2nd, McLendon RE, Desjardins A, 
Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles 
predict radiographic response and survival in malignant astrocytoma patients treated with 
bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271-8. Epub 2008/01/10. doi: 26/2/271 
(pii)10.1200/JCO.2007.13.3652. PubMed PMID: 18182667. 
 
16.       Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, 
Lassman AB. Patterns of relapse and prognosis after bevacizumab failure in recurrent 
glioblastoma. 
Neurology. 
2009;73(15):1200-6. 
Epub 
2009/10/14. 
doi: 
73/15/1200 
(pii)10.1212/WNL.0b013e3181bc0184. PubMed PMID: 19822869; PMCID: 2839807. 
 
17.       Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, 
Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy 
P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor 
tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma 
patients. Cancer Cell. 2007;11(1):83-95. Epub 2007/01/16. doi: S1535-6108(06)00370-9 
(pii)10.1016/j.ccr.2006.11.021 (doi). PubMed PMID: 17222792. 
 
18.       Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla 
JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic 
gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858-64. Epub 2004/07/06. doi: 
10.1038/nm1075nm1075 (pii). PubMed PMID: 15235597. 
 
19.       Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, 
Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou 
SP. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. 

Page 51 of 60 
Protocol Version 6.0 
 
Proc Natl Acad Sci U S A. 2011;108(9):3749-54. Epub 2011/02/16. doi: 1014480108 
(pii)10.1073/pnas.1014480108. PubMed PMID: 21321221; PMCID: 3048093. 
 
20. 
Lucio-Eterovic  AK,  Piao  Y,  de  Groot  JF.  Mediators  of  glioblastoma  resistance  and 
invasion    during    antivascular    endothelial    growth    factor   therapy.    Clin    Cancer   Res. 
2009;15(14):4589-99. PubMed PMID: 19567589. 
 
21.       Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, 
Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a 
monoclonal  antibody  against  vascular  endothelial  growth  factor  receptor-2.  Cancer  Res. 
2001;61(18):6624-8. Epub 2001/09/18. PubMed PMID: 11559524. 
 
22.       Zoula S, Rijken PF, Peters JP, Farion R, Van der Sanden BP, Van der Kogel AJ, Decorps 
M, Remy C. Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection. 
British  journal  of  cancer.  2003;88(9):1439-44.  doi:  10.1038/sj.bjc.6600837.  PubMed  PMID: 
12778075; PMCID: PMC2741029. 
 
23.       Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, 
Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta 
neuropathologica. 2007;114(2):97-109. 
 
24.       Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko 
C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and central nervous system 
tumors diagnosed in the United States in 2006-2010. Neuro-oncology. 2013;15(suppl 2):ii1-ii56. 
 
25.       Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of 
natural history and management options. Neurosurgical focus. 2006;20(4):E3. 
 
26 
Patel  et  al.  First-In-Human  Study of the  First-In-Class  Fatty Acid Synthase (FASN) 
Inhibitor, TVB-2640. Abstract session, AACR Annual meeting Monday April 20, 2015 
 
 
27. 
Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, 
Cahill DP, Chen P-J, Zhu M. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, 
normalizes  tumor  vasculature  and  alleviates  edema  in  glioblastoma  patients.  Cancer  cell. 
2007;11(1):83-95. 
 
28.      Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WA, 
Paleologos N, Nicholas MK, Jensen R. Bevacizumab alone and in combination with irinotecan in 
recurrent glioblastoma. Journal of Clinical Oncology. 2009;27(28):4733-40. 
 
29.       Maier T, Jenni S, Ban N. Architecture of mammalian fatty acid synthase at 4.5 Å resolution. 
Science. 2006;311(5765):1258-62. 
 
30. 
Shearn CT, Mercer KE, Orlicky DJ, Hennings L, Smathers-McCullough RL, Stiles BL, 
Ronis MJ, Petersen DR. Short term feeding of a high fat diet exerts an additive effect on 
hepatocellular damage and steatosis in liver-specific PTEN knockout mice2014. 

Page 52 of 60 
Protocol Version 6.0 
 
 
31.       Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic 
target in cancer. Future Oncology. 2010;6(4):551-62. 
 
32.       Mullen GE, Yet L. Progress in the development of fatty acid synthase inhibitors as 
anticancer targets. Bioorganic & Medicinal Chemistry Letters. 2015;25(20):4363-9. 
 
33.       Zhao W, Kridel S, Thorburn A, Kooshki M, Little J, Hebbar Sa, Robbins M. Fatty acid 
synthase: a novel target for antiglioma therapy. British journal of cancer. 2006;95(7):869-78. 
 
34.       Wakamiya T, Suzuki SO, Hamasaki H, Honda H, Mizoguchi M, Yoshimoto K, Iwaki T. 
Elevated expression of fatty acid synthase and nuclear localization of carnitine 
palmitoyltransferase 1C are common among human gliomas. Neuropathology. 2014;34(5):465- 
74. 
 
35.       Ventura R, Mordec K, Waszczuk J, Wang Z, Lai J, Fridlib M, Buckley D, Kemble G, Heuer 
TS. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor 
Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene 
Expression. EBioMedicine. 2015;2(8):808-24. 
 
36.       Brenner A. A Dual Phase 1, First –In-Human Study of Escalation Doses of Oral TVB-2640 
in Patients with Solid Tumors. (CTRC # 14-0028)2014. 

Page 53 of 60 
Protocol Version 6.0 
 
14. STUDY CALENDAR 
Screening 
 
Study Procedures 
(w/in 21 
days of 
C1D1) 
Cycle 1 
Cycle 2 
Cycle 3 
Cycle 4 
Cycle 5 
Cycle 6 
EOT G
 
 
 
Day 
Informed Cons ent 
 X 
Demographics 
X 
Med/Surg His tory 
 X 
Phys ical Exam (to 
include Advers e 
events and conc 
Day 
Day 
Day 
Day 
Day 
Day 
Day 
Day 
Day 
Day 
Day 
Day 
Day 
1 
15 
28 
1 
15 
1 
15 
1 
15 
1 
15 
1 
15 
meds )F 
X 
 XB 
  XB 
  XB 
 XB 
  XB 
 
 XB 
 
  XB 
 
  XB 
 
X 
Vital s igns 
X 
XB , I 
XB , I 
XB , I 
XB , I 
XB , I 
XB , I 
XB , I 
XB , I 
XB , I 
XB , I 
XB , I 
XB , I 
X 
Height 
X 
XB 
X 
X 
Weight 
X 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
X 
ECOG 
X 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
X 
CXR or CT 
X 
ECG 
X 
X 
MR-SPEC 
XB 
XB 
Serum SamplingH 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
Ophtalmology Eval. 
  X 
  
  
  XB 
 
  
 
  
 
  
 
  
 
 
  X 
Hematology labs 
 X 
  XB 
  XB 
 XB 
     XB 
  XB 
     XB 
   XB 
     XB 
  XB 
     XB 
  XB 
 XB 
 X 
Chemis try labs 
 XJ 
 XB 
 XB 
   XB 
   XB 
 XB 
   XB 
 XB 
   XB 
 XB 
   XB 
 XB 
   XB 
   X 
Coagulation labs c 
 
  X 
  
  
  
 
  
 
  
 
  
 
  
  
  X 
Urinalys is D 
X XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
XB 
X Pregnancy 
tes t 
  X 
 XB 
  
   XB 
 
 XB 
 
 XB 
 
 XB 
 
 XB 
 
 
   X 
TVB-2640 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
BevacizumabF  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Tumor Ass ess ment 
with Brain MRIE 
X 
XB E 
XBE 
XBE 
X 

Page 54 of 60 
Protocol Version 6.0 
 
B. 
 May be done up to 3 days prior to visit. 
C. 
INR only if pt is on warfarin 
D. 
Screen & EOT: UA with micro. Other visits, urine dipstick for protein & glucose. If positive or change from baseline, complete urinalysis w/ micro. 
E. 
Tumor Assessments: At  screening & after every even cycle (within 3 days) 
F. 
See dose level instructions in the protocol. Plus or minus 2 days. 
G. 
Occurs 3-4 weeks after the start of C6 or at least 2 weeks after the last dose of TVB-2640 for subjects who terminate early. 
H. 
Serum samples to analyze presence of Microvesicles (proteomic and lipidomic analysis) by standard centrifugation techniques. 
I. 
To be obtained predose and post-dose. 
J. 
Include standard Lipid Panel at Screening only. 

Page 55 of60 
Protocol Version 6.0 
 
APPENDIX A: EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE 
SCORE SCALE 
 
 
 
 
 
APPENDIX B: RANO TUMOR RESPONSE 
 
 

Page 56 of60 
Protocol Version 6.0 
 
APPENDIX C: Bevacizumab Dose Modifications 
 
 
 
 
Important treatment considerations -Dose modifications 
 
• There are no recommended dose reductions 
 
• Discontinue Avastin in patients with 
 
- Gastrointestinal(GI) perforati ons (GIperforations, fistul a formati on in the Gl tract,intra-abdominal 
abscess) 
 
- Fistula formation involving an internal organ 
 
- Wound dehi scence and wound healing complicati ons requiring medicalintervention 
 
- Seri ous hemorrhage [le,requiring medi calinterventi on) 
 
- Severe arterial thromboembolic event (ATE) 
 
- Life-threatening (grade 4) venous thromboembolic events,including pulmonary embolism 
 
- Hypertensive crisis or hypertensive encephalopathy 
 
- Posterior reversible encephalopathy syndrome (PRES) 
 
- Nephrotic syndrome 
 
• Temporarily suspend Avastin for:at least 4 weeks prior  to elective surgery,severe hypertension not  controlled 
with medicalmanagement,moderate to severe proteinuria,and severe infusion reactions 
 
• The safety of resumptoi n of Avastni therapyin pat ents that experienced PRES or ATE is unknown 

 
_- 
- 
-_ 
0.9
0.6 
-
... 
0.7
'"("""" 
0.4 
_· 
_
.!::.
>-
c.(UII tll t 
> 
'§ 
_ 
Q)
 
c 
>
-
CiolfiIt liMO)
.
(I)
-m 
('*t.et.414 .........
 
c
P,O_
I.18.M.80,) . 
-m 
s
...........  
0 
.0
 
 
 
FIGURE A 
BLOOD 
 
 
 
PS(IIOI'IIIrtllt 
II'$(U ttt&U.&{l'Z 1 .114t!J 
P$(1tttlm-211SZ.Iel.\l 
fiC(IUttl.llfVI'I.l(tl._tlf)j 
PS(I81ttZm2ttSl.lel.lt 
PC(I W112C.R.1U,II 
PC(!'C'i1&l{IIZ1.tl)) 
PSCUW221111lJt 
P$(110'nf(7l10l.tlllel)l 
t,ll--Ht 
PC((>-111)'20) 
PQI$(l11621__
9l,
IUJI
 
 
 
0.8 
t.f OI81ft2C0 
a.;tl1111120) 
P$(ttoo-ot 
fQ:I$0100) 
PE(0-16-<V»-61&%71IOZ 1ll16ZI 
MIP'CIIIIO'tl t 
PC(IICVI$1(14 
PG(22l(t)l.!Qjl'tt6(oll.1'l.t0l.l)l.16Z.1$l)) 
1.11.l41. . .,nocl0d 
1'¢(11"0100) 
PQt$ GC:•l.7Z,10Z.t3l,tQ,ttl» 
P$(130'2201 
PC(t• ••tllZ» 
PC(I$(V1&-}(tli('ZJJ 
(IfC1ZO<I(Sl,IZ,11LI.U:» 
4 
PC 
0.8 
P..Q..t...}.(.).ltUtRIUJt ... 
,a,U tSti IOd 
 
P((20S (.l l.t tl.t..,Z.IfZ)'00J 
P¢(1)QI'2t0(,4.'1Z.II:IttR.tt.tl 
l't(tlcno.tjlllt) 
Kill1(9l:m-016l.n.IOL.IU.t$tltl» 
lO(t71tiZY'7 t2zyt7:7tW-t2ZII 
 
l * f  
!id 
PC t).OO'UOI.Z,7Z.10Z.tU,I6Z.tOllO 
27l<SZ.IUOZ) 
t--f'IJIOIOry-t()oo:IO*tU 
,.. ......,..,....toe!
 
Cwldlll/2410) 
.-ltCMJ 
,... .ee- .o 
PQ!lQIOO) 
PC(tlCY20'($UlH.tt 
-·-  
 
 
O) 
(I) 
PQt)()'2041$l.U.ttl.14lt) 
S& l(dtll/200) 
PQt12l.tl.tKifl11\W.tt()J 
c..{dl81/2$0) 
PC(O-I..J)18JJ0 
41&Ztl11l.t 
P£-c..(d1-4 1(4EY20 
0 
P\'(He:(lr210) 
·;;: 
PQtOC)'Zfot 
0.2 
a. 
... 
._
.. 
... 
1'1(16CW'I611U).) 
PS(t7i)'12'C)J 
I'C(Ootf(m:l(fl.tCIZ.IU.IIZ,IIZJt 
c 
0.6 
00(11l(ll)rl71ltl)9011-:.l 
'f*/)' 
.Q  
OO(te..ttiiE)I'IOO'J'OJ 
... 
171(•.1(1 1 
.. l:tOIZ:t2tiSI.t  1 
· (I 
Pll,t 4  "!7l.10Lt ltl,1• 
(!) 
(!) 
0c 
0 
() 
MGtJ.OOO(),OOI(rK) 
t.IIH.I/2)0) 
e..{GIIIIU"O) 
0 
MGI1809'01001(rKJ 
.0 
.... 
(!) 
0.5 
PC((rt60fll lt$Z)J 
0 
-a; 
•m•rK.fl.tt£.t•ilt 
§.. 
0Cll.9'-t4(11'1ftl92ll 
Q) 
tlof(<tZ.n.toz tU) 
0:: 
MO ll,IIZ,I<Il)) 
.Q 
c..ld1f"21220) 
20&21 
0 
IQR·   P(lf' till)llt 
rtLKTLti.Z.t4Z·   -- 
P$(0"-16(11110. 
() 

 
0
0.4
(!)
-
,lo\41111Z4,0). 
()0
-0.4
· -
....,.,.. 
-- -
,..  ... 
-
,.,..... 
c 
(!) 
:2 
I'S(I10'121111lJl 
P$(111(tZV22'2tt)Z,Iel)t 
y-2Z.K7l.IIZ14l4              .-.d 
2 11)',...._Mii 
"
P$"(t"
t-1(9ZY12'4(7ZIOl13l-lelJ. 
.
1.
f2.
Q..
I..
4.
().
(.
4MtiMt(ll 
-0.2 
·o 
Celtolltf2< t(t5l» 
......,..,.,...,,.offrO'O..:rf.ll t<:CI 
!E 
 
 
 
 
0.3 
l1•\iUIV2tO) 
(!) 
CPAI.UIOJ 
I"S(0.2001203(1ZI1ZI ) 
P$(0-16'0120-ltll 
N-MM!Oyl....,_. 
sa.,'dtlt>?20) 
ll $l.MXI0Mt) 
-_ont2mt) 
P$(2'21(11l)Oot 
N-c.ftal$2(41IIV220i.2(lt(tl 
Oftt0$· ooy· • 
20<ti!ll.al:.11Z.Io&Zio00J 
PC(tt0120t<tUZ11l.t ij 
P${0-200119'HtZ» 
PC(<H.I)'204l,K.a11E 1'€11 
U.tt   lldd 
P'-(170001 
PS(CH&Oitfljtl» 
P(-c.rJ(II<IIl<l(l/100. 
SM..
:d.
l.
ll.
/1.
1.
0.
) 
.,..,e PA(t 7'"'0t 
47t01l,t............._.. 
N-lltl'fl'l  ..,_... 
PA(II 
S
 
0.2 
 
SM:otlti!OOJ 
 
I Z1 4'"1"   .R 
ttlQI.101.121X1Mf l7Wy 1$Mto) 
t 
tu;.;K t!HO) 
T l t t !   I( 
-4'0EZ 
llart7 1\   ,I 
 
 
0.1 
11..-&z:.tz,t:Z.Z,I$Z» 
"t140M 2 ·$llel)J 
c.t!Otl1tt.(IOI 
(2(1$11"')) 
"f -c.rtdl6 l(<litW 1(1 
 
P(:ti6.CVU-'fl'Z.10l,l)l.lallt 
MI'QIIII IIo,10H)) 
e,-fOII.It.14.0) 
1tE· 
1 
 
t•  2-tt·P 
 -0.6 
 
 
 
Page 57 of60  
0 
PS(IOt(tZV22'2tt)Z,IQ;It 
111 1(11 ) 
"!1101'20<1( UZ,IIl.l£flt 
C«<IIIO'tf t 
PA 4"-200100) 
1f2Q£.4f)(-w.(St 
f-1))·..,....,..1-rw.IIMI 
). f-ot'lt 
 
 
 
-0.8 
Protocol Version 6.v 
%hypoxia 

 
-
N_
.(l6010ot- 
-
TISSUE 
.... 
- "
HtY - 
- 
0.8
...-.--
.....
 
........... 
-- 
.... 
-
U-
(;(l6iii-
OOIOO',(r.ltj
 
0.2
c 
(j) 
PS(C)-t CY110)
- 
0.5 
.s. 
- 
-m
0
:::: 
c 
0
-
0
0c 
0 
.J:l
-m
.Q
Q;
03
 
 
 
H (:2A- ) "'Y(j 16,16 ·6l.$l, 
PCI,lHW2-<I) 
.,._,.._ 
7(11 ) 
1811\$  ) 
f'(,P-l8 ttwm <&l.ll..10l,116l,1WJJ 
Pl(IO"!Y'IO;{)t 
3H CINSWOtl t  .,._ 
c.
-.
o.
o.
o.-• 
A.nrw:I (20"S. 3t 
o iQ8J 
 
 
 
 
 
 
 
 
0.6 
0.9 
'PQC")-l'4 'tl01 
P$C2'0 6(1Z,IOZ.t ,le.lJI 
VJl.(19000) 
J'Cio-l•o-tat(tl:Jt 
Q,92:- 11·ol 
PCio-teO'tlll,'tl.12l» 
OI"U-GI'•l.7l,10l.n.Z.10il,IU» 
•,t..ll.15...1.U.I tetrtc:ONhe'.o.lnllltaod 
lf-llydloq-$,, 
o.o.,o.c.tt,e.O,.n.t.O..J.. 
--tc:llli 
.W aQ!dft"f 
PE,'P-1.000) 
P$Q02tlll.1<Cl)I22 L10i.ISZ.IIl)) 
0.4 
C9ftdtatnrOJ 
t,...,_,..2"'11C:0Mn01CIOO 
2$5(11l.IIZ.ItZJ2U 
:t•2......... 
PliO  t86 1UJ(tl_t2Z)O 
 
...,....,.(201n-t) 
...   . 
AA(1&31&Z9Z1ll)OOI 
t<C)IISl.IIZJilJ 
0.7 
•1.10.t)l     .:xj
 
2$-A.I: ci 
c.r(4itall110) 
H-bul)1 ll'flirll 
.
P CM 61t.i1(VJJ 
wttOS--Gtl l(ii) 
s r.._ 
17 Z IOd 
<0 
!...... 
- 
·x 
f'ltl40"l''tl)lt6lU 
0 
tdeoo10ca,;-t&t ..fJCll 
a.. 
>- 
.!:. 
 
811)'01:'0lly""lll octtiW.IeOt--911-dlyl'loelaO 
> 
0.6 
"PC"{' 018M2 1Z.IOZ,t3l,I4Z,t9l)) 
0::R 
c 
l$111lltw.JI  
(/) 
.Q 
f'CI.Q-160'180) 
00,191)'201llll)ll) l 
47 10131 taln0otaod 
(20"S t-3t 
> 
fi$(18 6C•Z.7Z.t0l.l)l.1&l,19lil 
Q) 
Q)  
PI((H$0'11'0) 
PS(20 ttt1Zit 
2--om- tci6 
0 
PCto-•e<rn:«.a.t 'l.•Ol.IJl.t6l.•W» 
0 
4 7,10.1).. 
?o-:o-  tcoct 
m 
Q) 
11 ·oa..decei'IOI(.oel 
Q; 
ICOI Kd  
0 
te21:2C. . 
47,10.1'-docc4 
PQI)O'UI!(<Il.7Z10l.l)l,lel_1tl)) 
(j) 
0:: 
l•(t•2-(81  ftlt--«UU)  
c 
PlUG 1 6(7l,IOZ.IlL1GiQ) 
PS(201{11lVD Z.IOZ,I,18lJI 
, ..: 7l.10l,lll.l 
to-tlydlo· ""' 
H-oleoo!t..,... 
0 
P£t()oi !Y'Ial(tl.IU.1 )
 
 
f l tl{4t• 1(4fY2• t(ISon) 
.J:l 
P$(111(tl)ttt(•Z.7Z.IOZ.13l.IIZ.IN)) 
- 
·  
...  
-9(;U 
m 
PCkta.tfllliOOI 
0 
1001"431 
0.4 
0 
"'120f222(UZ,Iaz)) 
PCj()-1.0'22-o) 
PO(II(Itlt•OJ 
•t.t2.15.1 1od  
Q) 
11,1 
- 
"(3 
2tt(IIZ.I.U.t7Z.2CZ) 
2Nt,dr 2· 
1U12l.4f tl.IE.12£.t•l(Wt1Mt IOMI($].13Mt) 
I'C(IIOII'l41(1SZ)) 
tt tcd 
-0.2   
Q)
 
,.,..0100) 
H:f()-IC I(CZ,7Z,10l.t3Z,IQ.t9f» 
OGtllOitl l(tl)OO)IdJ 
21t ·t,clr   .od 
Q:-MQtfi_,....,.....I!M 
17114){1..... 
fiC4tCcrM1(SUl)) 
PG<1"'(!ti»);U.11Z.t4ln 
PliO.t861ttt('tlJ} 
PS(It C)t 
(1Uril 
fiC{l-t.OrrlU(ctl'IIOI131_tUt9!)) 
PCI,t t ot 
W(l(IIQIIOQIO 
I'C(t80fll2(10l12Z)) 
 
OO(P-t•o+t$1CWJ) 
 
 
 
 
 
 
 

 
·-
-0.4
-0.6
"""""'""" 
Protocol Version 
 
 
 
 
Page 58 of60 
 
 
0.2 
 
 
 
 
 
 
0.1 
00(21 Ml.I(IU)ot.o'.(u21 
eo-- 
1'1(110®- .&l,IIZIU)) 
··ot•t J»ttleM 
PCtt5()'t81(1ll)) 
l'll,o-tii61Ui(9Z.Ul)) 
N.(IJ:QIO(lf 
PCtttCW22C(CZ  1Z tOZI:lZ  I&ZIQZ)) 
16 i'f' 4F)(a.r. 
(9$.10S)-to-  1Ci 
PCI,tt0'204¢rl-821tl.t.cZ)) 
&  1)- ll teid 
I'C(IOOO'O-o) 
N.(P·I-6000J 
19t(gzy22"(1Z.IOZ.13l,.t 2U 
f'C(18 161(Wl. 
P$ttS{)'2}-0t 
PC{I,Or'lO"{lrl,U,IIl,l•) 
PCtt80'181(9l.u 
PQ,t.6tvl!lt("'» 
"ttS0'222(t:)l.l$tlt 
P)\(()-1 1)100) 
Pl{lllOO(J) 
$Mici1&2Q.I1) 
fiC(II71.W.IUVl2-15C•l.7Z.IOl,IU.16l,lillt 
16010-0) 
PG<te:Ottl,lflbt 
f'Cet.GOr'lO.'I; U.11Z.14l)) 
PCil-$012-.c(12.tOZ,t3l.lo$Zit 
P$111CYZ2ot 
f'OIIaO'Ja<' "Z» 
PC(I7:0't81(9lJI 
1-o.:o- 
P$:170t22:1flln. 
PJr(C)-I Qr1 11'l)) 
Otftl;1101teOC20Hlt 
(d1Sl("UE)'22.0(20t()J 
PI(I$0'22'1(HZ)) 
PO(UI(tE)IIll{lflt 
0 
PC(IOM2.o) 
0 7 09 63  7   8.1   10  10611 i 
13 18.723.1     % 
hypoxia 

Page 59 of 60 
Protocol Version 6.0 
 
BLOOD 
 
 
 
 
 
 
 
 
 
TISSUE 
 
 

Page 60 of 60 
Protocol Version 6.0 
 
5
PLASMA VS TISSUE HYPOXIA 
 
 
 
 
 
180 
 
u 150 
c 8 120 
X
 
90 
..  60 
 
r  U./, p ' U.UL 
 
 
 
+ 
 
 
 
 
.. +---- 
 
• 
--- 
..  30 ... 
 
.-----:--;+ 
+ 
.... 
li: 
0 
 
-30 
 
°
B'o-- 
5% 
10% 
15%  
20% 
Tissue CA·IX Positive Cell %